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Hypoxia-ischemia in the perinatal period is an important factor affecting the 
proper development of the brain. Although different regions of the developing brain 
are affected by hypoxia, the periventricular white matter (PWM) is highly vulnerable 
to damage. The pathogenesis of PWM damage (PWMD) has been reported to be 
multifactorial, inflammation being recognized as a major factor. Amoeboid microglial 
cells (AMC), the nascent form of microglia, are active macrophages and are present in 
large numbers in the developing PWM. It is well documented that microglial cells 
play a crucial role in the modulation of inflammatory response in the central nervous 
system (CNS). Astrocytes are also implicated in inflammatory response in the CNS 
under pathological conditions. However, the role of AMC and astrocytes in PWMD in 
neonatal brain under hypoxic conditions has not been fully elucidated. The present 
study was undertaken to investigate their role in PWMD in hypoxic conditions. The 
potential mechanisms and signaling pathways by which AMC and astrocytes induce 
oligodendrocytes and axon damage in hypoxic conditions were also examined. To 
address these, both in vivo & in vitro studies were carried out. 
For the in vivo experiments, Wistar rats (1-day old) were subjected to hypoxia 
(5% oxygen and 95% nitrogen), following which upregulated mRNA and protein 
expression of tumor necrosis factor-α (TNF-α), interleukin-1β (IL-1β), TNF receptor 
1 (TNF-R1) and IL-1 receptor 1 (IL-1R1), monocyte chemoattractant protein-1 
(MCP-1) and its receptor (CCR2), macrophage-colony stimulating factor (M-CSF) 
and CSF-1 receptor (CSF-1R) in the PWM was observed. Immunofluorescence 
labeling of TNF-α, IL-1β, MCP-1, CCR2, and M-CSF expression was specifically 
 xiv
Summary 
colocalized in AMC from 24h-7d after hypoxic exposure. However, at a late stage of 
injury i.e 7 and 14d following hypoxic exposure, CSF-1R, TNF-α and IL-1β 
immunoexpression was detected in the astrocytes in the same area. TNF-R1 and 
IL-1R1 immunoexpression was localized in the oligodendrocytes and axons of the 
PWM. This was coupled with apoptosis and reduction in the number of 
oligodendrocytes and swelling and disruption of axons. Another striking feature in 
hypoxic rats was a marked increase in cell numbers of AMC in the PWM. BrdU 
immunostaining showed that there was no significant change in the proliferation rate 
of AMC after hypoxic exposure suggesting that the increase in numbers may be due to 
migration of AMC from the nearby regions such as the cerebral cortex. When MCP-1 
(100ug/mL) was injected intracerebrally into the PWM of 7-day old postnatal rats, it 
induced the chemotactic migration of AMC to the injection site. 
For the in vitro studies, primary cultured microglial cells were subjected to 
hypoxia (3% oxygen, 5% CO2 and 92% nitrogen). They showed enhanced expression 
of TNF-α, IL-1β, MCP-1 and M-CSF. MAP kinase signaling pathway was implicated 
in the expression of TNF-α and IL-1β in microglia subjected to hypoxia. Furthermore, 
NF-kappaB signaling pathway was involved in release of MCP-1 from microglia 
subjected to hypoxia. Primary cultured astrocytes treated with M-CSF exhibited 
increased expression of CSF-1R, TNF-α and IL-1β. In addition, it was also shown that 
MAP kinase signaling pathway was involved in TNF-α and IL-1βexpression in 
astrocytes which were subjected to M-CSF treatment. In the in vitro chemotaxis assay, 
the medium derived from hypoxia-treated microglial cultures attracted more 
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migratory microglial cells than that from the control microglial culture. 
This study has revealed that in the early phase of injury following hypoxic 
exposure, microglial cells in the PWM in the neonatal brain produce inflammatory 
cytokines such as TNF-α and IL-1β via MAP kinase signaling pathway. An increase in 
MCP-1 production via NF-kappaB signaling pathway in AMC following hypoxic 
exposure induces the migration of AMC from the neighboring areas to the PWM. 
Undoubtedly, this would augment the inflammatory response in the PWM of the 
hypoxic neonatal rats and aggravate PWMD. M-CSF produced by AMC in the early 
phase of injury interacts with its receptor, CSF-1R, which was located on the 
astrocytes. The possible interaction between AMC and astrocytes via M-CSF and its 
receptor would lead to release of proinflammatory cytokines such as TNF-α and IL-1β 
from the latter cell type via the JNK kinase signaling pathway at the late phase of 
injury following hypoxic exposure. Therefore, in the course of the inflammatory 
response in the PWM of the neonatal rats following a hypoxic injury, AMC might 
contribute to inflammation at the early phase and astrocytes at the late phase. 
Concomitantly, TNF-α and IL-1β interact with their respective receptors expressed on 
the oligodendrocytes and axons. This would lead to apoptosis and reduction in the 
number of oligodendrocytes, degeneration of the axons as well as delay in their 
myelination. Therefore, these inflammatory cytokines and chemokines are detrimental 

















Cerebral white matter is located in the deep parts of the brain and occupies 
nearly one half of the brain volume (Zhang and Sejnowski 2000; Filley 2005). It is 
made up of axons and glial cells, including oligodendrocytes, astrocytes and microglia 
(Filley 2005). The axons are arranged regularly and form neural fiber tracts, which 
play a crucial role in neural information transmission (Dougherty et al. 2005). 
Oligodendrocyte processes contact and repeatedly envelope a stretch of axon to form 
multispiral myelin sheath. Axons in the neonatal brain are not myelinated. 
Myelination of axons in the periventricular white matter (PWM) of developing rat 
brain was first observed at the end of the first postnatal week and progresses rapidly 
over the next 2-3 weeks (Sturrock 1980). In the course of rat brain development the 
process of axonal myelination is divided into three phases: (i) premyelinating before 
postnatal 7 day (P1-7), (ii) early myelinating which is present around 10 days (P10), 
and (iii) late myelinating which appears around postnatal 21 day (P21) (McCarran and 
Goldberg 2007). The disruption of these axons and myelin sheath cause disorders of 
neural networks function resulting in some neurobehavioural abnormalities (Mulhern 
et al. 2001; Filley 2005). 
Hypoxia-ischemia and inflammation occurring in the perinatal period result in 
the white matter injury which is one of the major causes of neonatal mortality and 
neurological defects such as cerebral palsy, impaired vision, hearing impairments and 
mental retardation in premature newborns (Volpe 2003; Vannucci 2005). The PWM, 
peripheral to the lateral ventricles (Fig.1), is vulnerable to damage in the perinatal 
period (Folkerth 2006). The vulnerability may be attributable to the existence of 
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widespread oligodendrocyte progenitors and lack of anastomoses of blood vessels in 
this area (Folkerth 2006).  
The pathogenesis of PWM damage (PWMD) is complex and is not fully 
elucidated. Studies have shown that a common feature of PWMD is injury to the 
axons and developing oligodendrocytes before myelination occurs (Dammann et al. 
2001). Activated immune cells are believed to play a crucial role in damaging axons 
and oligodendrocytes through producing inflammatory mediators (Yamasaki et al. 
1996). It has also been found that excess extracellular glutamate causes death of 
oligodendrocyte progenitors through glutamate receptor-regulated excitotoxicity 
leading to PWMD (Volpe 2001; Folkerth et al. 2004). 
1.1 Etiology and risk factors associated with PWMD 
There are several possible perinatal risk factors that have been reported to be 
associated with PWMD.  
1.1.1 Immaturity 
The immaturity of the fetus is the most common risk factor related to PWMD 
(De Vries et al. 1988). When the subjects are born prematurely before 34 gestational 
weeks, they are vulnerable to PWM lesions (Jacobson et al. 2006). White matter 
damage of immaturity may affect visual, motor and cognitive functions (Jacobson et 
al. 2006). Neuroimaging studies of very low birth weight (VLBW) survivors suggest 
that the cerebral palsy, cognitive/behavioral deficits correlate with the focal or diffuse 





Hypoxia/ischemia is another important factor affecting the normal development 
and maturation of the CNS. Many maternal causes such as diabetes, asthma, anemia 
and smoking and intrapartum events such as prolonged labor are associated with fetal 
hypoxia/ischemia (Sugai et al. 2006). In the neonates, pulmonary or cardiac 
dysfunction and neonatal stroke result in hypoxia/ischemia (Mu et al. 2003).  
1.1.3 Infection 
Apart from cerebral hypoxia-ischemia, another important prenatal risk factor is 
most likely to be intrauterine infection, which causes premature delivery and increases 
fetal morbidity in preterm infants (Vigneswaran 2000). Infections of the amniotic 
fluid, decidua or placenta and overproduction of inflammatory cytokines are believed 
to be important contributing factors which promote spontaneous rupture of the 
membranes and preterm labor prior to 30 gestational weeks (GW) (Baud et al. 1998). 
In particular, asymptomatic bacterial vaginosis in the mother is ranked No.1 among 
the pathogen-induced infections related to premature delivery (Baud et al. 1998). 
Several epidemiological studies have reported that chorioamnionitis is a primary 
causative factor for fetal neurological disturbance and cerebral palsy (Baud et al. 
1998). Chorioamniotic infection leads to the fetal brain and lung tissue injuries 
through overproduction of pro-inflammatory cytokines as well as the activation of 






In the past decades, the fetal and neonatal inflammatory responses under various 
pathological conditions have been found to contribute to PWMD (Rezaie and Dean 
2002). Overproduction of inflammatory mediators including TNF-α, IL-1β and 
interleukin-2 (IL-2), interleukin-6 (IL-6) as well as adhesion molecules such as 
vascular cell adhesion molecule-1 (VCAM-1), intercellular adhesion molecule-1 
(ICAM-1) has been involved in the pathogenesis of PWMD (Kadhim et al. 2001). 
Free radicals and excitotoxic-mediated damage associated with inflammatory 
response have also been considered to be implicated in PWMD (Rezaie and Dean 
2002).  
1.1.5 Vascular factors 
It has been shown that due to the relatively low vascularity of white matter in 
comparison with the gray matter, hypoxia/ischemia is likely to facilitate the 
pathogenesis of PWMD (Ballabh et al. 2004). The astrocyte end-feet contacts play a 
pivotal role in the maintenance of the structural integrity of the cerebral blood vessels 
(El-Khoury et al. 2006). The blood vessels in the PWM of neonatal rats are thin 
walled and many of them are lack of the astrocyte end-feet contacts (El-Khoury et al. 
2006). It has been reported that the permeability of the cerebral blood vessels is 
upregulated in hypoxic conditions (Kaur et al. 2010). This was coupled with increased 
expression of VEGF in astrocytes and endothelial nitric oxide synthase (eNOS) in the 
blood vessel endothelium (Kaur et al. 2006b). Moreover, clinical and experimental 
data demonstrated that cerebrovascular autoregulation disturbance in the premature 
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infants is associated with a high likelihood of occurrence of PWMD (Tsuji et al. 
2000). 
1.1.6 Other risk factors 
Other proposed factors that are implicated in the PWMD in the neonate include 
genetic factors, multiple pregnancy, bradycardia, pre-eclampsia, bilirubin toxicity, 
intrauterine growth retardation, deficiencies in trophic factors as well as hyaline 
membrane disease (Resch et al. 2000; Saliba and Marret 2001).  
1.2 Pathological changes in the PWMD 
PWM lesions range from cystic necrosis of the PWM to myelination disorders 
(Skoff et al. 2001). Axonal swelling, microglial activation, astrocytosis and 
oligodendroglial injury have been reported in the PWMD (Skoff et al. 2001). Swollen 
and degenerating axons in the PWM in the neonatal rat brain after hypoxic exposure 
have been found (Kaur et al. 2006a). Along with the above, necrotic and apoptotic 
cells were observed at different time points in hypoxic neonatal rats (Kaur and You, 
2000). Concomitantly, it has also been found that AMC phagocytosed the 
degenerating axons, necrotic and apoptotic cells (Kaur and You, 2000). The necrotic 
cystic cavities were formed in the PWM in later stages (Cai et al. 2001). This is also 
accompanied by impaired or delayed myelination (Cai et al. 2001). Reduced myelin 
basic protein (MBP) after hypoxic exposure suggested that myelination process was 
altered in the PWM (Biran et al. 2006; Kaur et al. 2006a). Several studies have shown 




1.3 Oligodendrocytes development, maturity, myelination and injury in the 
PWMD 
Oligodendrocytes are the myelin-forming cells in the CNS which originate from 
neuroepithelial cells of the ventricular zones in the very early period of embryonic life 
(Thomas et al. 2000). The subventricular zone (SVZ), which appears in late 
gestational and early postnatal mammalian brain, is the main source of 
oligodendrocytes and astrocytes (Thomas et al. 2000). Oligodendrocyte progenitors 
migrate to developing white matter tracts and undergo substantial proliferation before 
their final differentiation into myelin-forming cells (Thomas et al. 2000). Different 
developmental stages of the oligodendrocyte lineage can be identified by a panel of 
cell specific antibodies, which are regarded as the sequential expression of 
oligodendrocyte developmental markers such as A2B5, O4, O1, MBP, and myelin 
proteolipid protein (PLP) (Back et al. 2001). Some researchers have defined four 
successive development stages of oligodendrocytes during gestation as follows: (i) 
early oligodendrocyte progenitors (A2B5+); (ii) late oligodendrocyte progenitors 
(pre-OL), which are present from ∼18 GW, specifically express platelet-derived 
growth factor-α (PDGF-α) receptor and are positive for the antibody O4 as well as the 
proteoglycan NG-2; (iii) immature oligodendrocytes (adenomatus polyposis coli 
(CC1+), O1+) appear between 18 and 27 weeks; and (iv) mature oligodendrocytes 
(MBP) which are present around 30 GW (Back et al. 2001).  
Myelination is a complex physiological process which consists of the spiraling of 
the oligodendrocyte process around the axon. The mechanism of myelination or the 
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signals that modulate this complex process have not been elucidated. The steps 
involved in the process are as follows: 1) Oligodendrocytes migrate to the vicinity of 
the axons that are to be myelinated; 2) The oligodendrocyte process adheres to the 
axon; and 3) The process spirals around the axon with the formation of a large number 
of myelin sheaths and some unmyelinated space is recognized as the node of Ranvier 
(Baumann and Pham-Dinh 2001). 
The hallmark of PWMD occurring primarily in preterm infants is 
oligodendrocyte progenitor injury. The period of the greatest risk for PWMD is 
approximately to 23-32 weeks postconception in humans (Pang et al. 2000). In this 
period, oligodendrocyte precursors dominate in the PWM and myelin sheaths are not 
synthesized (Pang et al. 2000). Some researchers have demonstrated that immature 
oligodendrocytes during the specific prenatal window were vulnerable because of lack 
of the antioxidant enzymes such as Manganese (Mn) and CopperZinc (CuZn) 
superoxide dismutases as compared to mature oligodendrocytes (Mitrovic et al. 1994; 
Ludwin 1997; Kinney and Back 1998; Folkerth et al. 2004). In addition, 
premyelinating oligodendrocytes express cytokine interferon- γ  receptor and 
α-amino-3-hydroxy 5-methyl-4-isoxazolepropionic acid (AMPA) recptor (Folkerth 
and Haynes et al. 2004;Talos et al. 2006). Therefore, developing oligodendrocytes are 
susceptible to free radical injury, inflammatory mediators and excitotoxicity. 
At present the specific mechanisms responsible for developing oligodendrocyte 
injury have not been fully elucidated. But, glutamate excitotoxicity, free radical and 




Glutamate is the predominant excitatory neurotransmitter in the CNS. Actions of 
glutamate are modulated by activated metabotropic glutamate receptors (mGluRs) and 
ionotropic receptors such as [N-methyl-d-aspartate (NMDA), AMPA and kainite 
receptors (KA)]. It is well known that oligodendrocytes express both ionotropic and 
metabotropic glutamate receptors (Káradóttir et al. 2005; Deng W et al. 2004). 
Therefore, excessive glutamate released from disrupted axons in hypoxic-ischemic 
brain results in excitotoxicity towards oligodendrocytes (Oka et al. 1993). Activation 
of glutamate receptors mediates Ca2+ increase and initiates a cascade of biochemical 
effects in immature oligodendrocytes leading to PWMD (Cai et al. 1995; Micu et al. 
2006). 
Hypoxia/ischemia is well documented to induce free radical reactions, leading to 
overproduction of reactive oxygen species (ROS) (Sum et al. 1998). Excess 
production of ROS has been describled to be harmful to immature oligodendrocytes 
(Haynes et al. 2005). ROS preferentially injure vulnerable premyelinating (O4+ and 
O1+) oligodendrocytes, resulting in their loss, subsequent decreased numbers of 
mature oligodendrocytes, and hypomyelination (Haynes et al. 2003). Activated 
microglia have been considered as the main source of ROS (Domercq et al. 2007). In 
vitro studies have reported that increased level of ROS was produced by microglia in 
hypoxic conditions (Kaur et al. 2009).   
It has been reported that the activated cytokine receptors were involved in 
oligodendroglial necrosis or apoptosis not only in the pathogenesis of adult 
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demyelinating disorders but also during development (Casaccia-Bonnefil 2000). The 
activation of cytokine receptors on the surface of oligodendrocytes can cause the 
necrosis or apoptosis of these cells through cross-talk between ligand and receptors, 
which activates intracellular signaling pathways related to apoptosis and energy 
metabolism disruption (Casaccia-Bonnefil 2000). Some in vitro studies have 
demonstrated that the proinflammatory cytokines such as TNF-α and 
interferon-gamma (IFN-γ) induce apoptosis of cultured oligodendrocytes through the 
activation of 'death' receptors including Fas and TNF-R1 expressed on their surface 
(Pouly et al. 2000; Torres et al. 1995). 
While under physiological conditions, microglia and astrocytes have been proven 
to contribute to the survival, differentiation and maturity of oligodendrocyte 
progenitors, activated microglia and astrocytes under pathological conditions can lead 
to oligodendroglial damage through release of various proinflammatory cytokines 
(Ohno and Aotani 2000; Pang et al. 2000). In vitro studies have shown that bacterial 
lipopolysaccharide (LPS) alone has no direct toxic effect on oligodendrocyte 
progenitors (Pang et al. 2000). However, oligodendroglial apoptosis is induced by 
conditioned medium which originated from microglia or astrocyte cultures 
administered with LPS (Pang et al. 2000). So the toxic effects of LPS on 
oligodendrocyte progenitors are due to activation of microglia and astrocytes (Pang et 
al. 2000). The extent of oligodendrocyte precursor damage in vivo has been thought to 




1.4 Axon injury in the PWMD 
The axon is the elongated fiber that extends from the neuronal body to the 
terminal endings and transmits information. The larger the axon, the faster it transmits 
the neural signal (Baumann and Pham-Dinh 2001). Most axons are covered with a 
fatty substance called myelin that acts as an insulator (Baumann and Pham-Dinh 
2001). These myelinated axons transmit the neural signal much faster than the 
non-myelinated ones. In normal myelinated axons, Na+ channels are concentrated at 
nodes of Ranvier, which accelerate signal transduction through allowing the action 
potential to rapidly jump from node to node (Baumann and Pham-Dinh 2001). The 
axons are not myelinated in the neonatal animals. In hypoxic rats, the swollen and 
degenerating axons observed under the electron microscope were described as the 
most conspicuous feature between 3 h and 7 days after the hypoxic exposure (Kaur et 
al. 2006a). Quantification of the degenerating axons in the PWM showed a 
significantly higher number of degenerating axons in the hypoxic neonatal brain 
(Kaur et al. 2006a). Many of the degenerating axons in the hypoxic rats appeared to 
have lost the axoplasm and appeared to be empty (Kaur et al. 2006a). Very few axons 
were found to be myelinated in the hypoxic 7-day-old rats, and the myelin sheaths of 
these axons appeared completely distorted (Kaur et al. 2006a). Moreover, the 
degenerating axons were predominantly found in the vicinity of the cerebral blood 
vessels in the hypoxic rats (Kaur et al. 2006a). 
Mechanisms of axon injury are complex and remain unclear. Some studies have 
demonstrated that premyelinated white matter axons in isolated rodent optic nerve 
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were highly resistant to hypoxic-ischemic injury, whereas early and late myelinating 
white matter axons were increasingly vulnerable (Fern et al. 1998). Several 
mechanisms of hypoxic-ischemic axonal injury have been proposed. Energy depletion 
during hypoxia-ischemia leads to failure of energy-dependent extracellular and 
intracellular ionic balance, resulting in axonal Ca2+ overload, conduction damage, and 
structural injury (Stys 2005). Excessive glutamate receptor activation, or 
excitotoxicity, results in ischemic white matter axon injury, as shown by intracerebral 
injection of AMPA (Cuthill et al. 2006). AMPA/kainite receptors participate in 
ischemic injury to myelinated white matter axons in vivo, but not to isolated axons. 
Studies have shown that ionotropic glutamate receptor agonists did not damage 
isolated axons, nor did glutamate receptors antagonists protected isolated axons from 
oxygen-glucose deprivation (McCarran and Goldberg 2007). Therefore, excess 
glutamate may induce white matter axon injury by causing damage to myelinating 
oligodendrocytes. It has been reported in some studies that axonal injury in 
myelinated white matter results from oligodendrocyte excitotoxicity and can be 
prevented by blockade of oligodendrocyte AMPA/kainate receptors (McCarran and 
Goldberg 2007). The mechanisms linking oligodendrocyte injury to axon damage 
might include release of toxic substances from injured oligodendrocytes, loss of 
trophic support to axons, or loss of glial homeostatic functions (Fowler et al. 2006). 
Attenuation of oligodendrocyte-myelin-axon interactions in myelinated white matter 
decreases axonal injury after AMPA injection (Fowler et al. 2006). However, 
interaction between axons and immature oligodendrocytes is weak in premyelinated 
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white matter. Some studies have reported that prevention of oligodendrocyte 
excitotoxicity does not decrease premyelinated axonal damage (Fowler et al. 2006). 
Therefore, oligodendrocyte excitotoxicity does not result in axonal damage in 
premyelinated white matter (McCarran and Goldberg 2007). Axons in premyelinated 
white matter suffer from hypoxic/ischemic injury through a non-excitotoxic way 
(McCarran and Goldberg 2007). The mechanism of axonal injury likely includes 
failure of ionic homeostasis and intra-axonal Ca2+ overload, as mentioned above 
(McCarran and Goldberg 2007). The downstream pathways of Ca2+-induced axonal 
injury remain unclear. 
In addition, activation of cytokine receptors has also been involved in axonal 
injury. The activation of cytokine receptors on the surface of axons can result in their 
damage by interaction between ligand and receptors, which triggers intracellular 
signaling pathways associated with apoptosis and energy metabolism depletion (Tezel, 
2008). 
1.5 Role of astrocytes in the PWMD 
Astrocytes, the primary glial cell type in mammalian CNS, have been found to 
execute some critical functions including generation of nutrient and growth factors,   
scavenging free radicals, maintenance of blood brain barrier (BBB) integrity, ionic 
homeostasis and uptake of neurotransmitter (Panickar and Norenberg 2005; 
Nedergaard et al. 2003). Astrocytic end-feet form an envelope around the blood 
vessels and astrocytic processes extend to beneath the pial membrane and ependymal 
surface, thereby separating the CNS parenchyma from the external environment 
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(Panickar and Norenberg 2005). Astrocytes can uptake the excitatory amino acid 
glutamate from extracellular fluid surrounding the synaptic cleft, which is critical for 
optical glutamatergic neurotransmission and for preventing cellular excitotoxicity 
(Danbolt 1994). Furthermore, astrocytes also can take up and buffer excess 
extracellular K+ released from neurons which prevents the accumulation of 
extracellular K+ during neuronal depolarization (Panickar and Norenberg 2005). 
Another important physiological role of astrocytes is their ability to supply neurons 
with substrates of glycogen metabolism that might be pivotal in states of energy stress 
(Dringen et al. 1993). Thus it is clear that the physiological functions of astrocytes are 
multifaceted and complex.  
Cerebral white matter astrocytosis is one of the characteristic pathological 
changes in the PWMD (Hirayama et al. 2001). It occurs in approximately 15-40% of 
neonates who had suffered from hypoxia-ischemia (Rezaie and Dean 2002). The main 
feature of astrogliosis is described as cellular hyperplasia, hypertrophy and 
upregulated expression of glial fibrillary acidic protein (GFAP) (Zhu et al. 2006). 
Astrocytic responses may be helpful to the repair of the PWMD. However, excessive 
astrogliosis may be harmful and contribute to axonal or oligodendroglial injury 
(Zawadzka and Kaminska 2003). Astrogliosis along with extracellular matrix results 
in scar-formation at the injury site (Di et al. 2005). The scar comprising reactive 
astrocytes can prevent axonal regeneration and reestablishment of synapse after injury 
in the CNS through forming a local biochemical and physiological barrier (Di et al. 
2005). Furthermore, excessive astrogliosis may be another source of proinflammatory 
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cytokine production in the PWM besides microglia. Therefore, early inhibition of 
astrogliosis would help to alleviate the white matter injury (Di et al. 2005). 
Vascular endothelial growth factor (VEGF) is not only an angiogenic growth 
factor whose expression induces vasculogenesis, but it is also described as a vascular 
permeability enhancing factor (Croll et al. 2004). Some studies have shown that 
up-regulated VEGF expression is located in astrocytes in the vicinity of the foci of 
necrosis in PWMD, and may participate in white matter lesion (Ment et al. 1997). The 
expression of VEGF is increased after hypoxic exposure, which plays a pivotal role in 
the pathogenesis of vascular leakage in the hypoxic brain leading to the formation of 
cerebral edema (Kaur et al. 2006). Many VEGF positive astrocytes were found to be 
present around the blood vessels in the PWM in hypoxic neonatal brains (Kaur et al. 
2006). The precise mechanism by which VEGF results in vascular hyperpermeability 
is still not clear. It has been reported that VEGF-mediated zonula occludens-1 
expression at the tight junctions of the endothelial cells were involved in 
hypoxia-induced hyperpermeability of the cerebral blood vessels (Dobrogowska et al. 
1998). VEGF is also well-known to induce changes such as fragmentation of the 
endothelium, fenestration of the endothelial cells, appearance of interendothelial gaps 
and degenerative changes in endothelial basement membrane in microvascular 
segments which disrupt the structural integrity of the cerebral microvessels and causes 
extravasation of blood plasma proteins such as albumin (Dobrogowska et al. 1998). 
VEGF expression was located in both astrocytes and endothelial cells in vessels that 
comprised neovascularization in the vicinity of necrotic foci in brains with PWMD 
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(Arai et al. 1998). Besides modulating the vascular permeability, VEGF may also 
participate in inducing inflammatory responses in the PWM (Arai et al. 1998). 
Therefore, VEGF has been regarded as a proinflammatory mediator which 
exacerbates inflammatory responses observed in cerebral ischemia. VEGF regulates 
immune responses in the CNS by potentiating vascular permeability and inducing 
BBB breakdown. This leads to occurrence of cross-talks between normally 
sequestered CNS antigens and blood-borne immune mediators, and hence, the 
immune privileged status of the brain is altered (Proescholdt et al. 1999). Because of 
its proinflammatory functions, VEGF induces the adhesion of leukocytes to vascular 
walls and enhances ICAM-1 and VCAM-1 expression (Min et al. 2005). 
Overexposure of normal brain to VEGF has been observed to increase ICAM-1 and 
major histocompatibility complex (MHC) class Ⅰand Ⅱexpression (Min et al. 2005). 
It is speculated that VEGF may induce inflammatory response in the hypoxic neonatal 
brain leading to PWMD (Min et al. 2005). 
1.6 Role of microglia in the PWMD 
AMC, present in large numbers in the developing PWM (Ling and Wong 1993), 
are resident immune cells in the CNS. Although microglial cells are necessary for 
normal functions, their overactivation can result in bystander damage to other CNS 
cells. Activated microglia have direct toxic effects on oligodendrocytes in culture 
through release of NO (Mitrovic et al. 1996). Some studies have found that TNF-α 
secreted by activate microglia was capable of killing oligodendrocytes (Zajicek et al. 
1992). Based on these findings, it appears that NO and TNF-α produced by activated 
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microglia are involved in oligodendroglial death. Furthermore, activated microglia 
may induce oligodendrocyte injury through complement-induced phagocytosis and 
direct cell-cell contact (Rezaie and Dean 2002). There are ample evidences to suggest 
that microglia not only trigger PWMD, but also contribute to the development of 
lesions in the PWM (Rezaie and Dean 2002). 
1.6.1 Origin and morphology of microglia 
Microglia constitute 5-20% of all glial cells in the CNS. The developmental 
origin of microglia has been controversial for many years since Rio-Hortega 
described for the first time microglia as a cellular “third element” besides the neurons 
and neuroglia in the CNS (Kaur et al. 2001). At present, three main schools of thought 
are associated with the origin of microglia: (1) mesodermal, (2) neuroectodermal, and 
(3) monocytic (Ling, 1977; Kaur et al. 2001). Most researchers support the hypothesis 
that microglia are derived from blood monocytes and/or their hematopoietic 
precursors (Ling, 1977, 1980; Kaur et al. 2001). Immigration of microglial precursors 
into the developing CNS occurs during the late embryonic and early postnatal periods 
(Dalmau et al. 1998), and this influx of cells, which gradually increases in number 
and transform into mature ramified cells, is considered the basis for acquisition of the 
adult microglial cell population (Dalmau et al. 2003). 
Two microglial phenotypes have been described: AMC and ramified microglial 
cells (Kaur et al., 2001). In the developing brain, the preponderant AMC exhibit a 
round cell body with some processes (Kaur et al., 2001). These cells transform into 
ramified microglial cells with the development and maturity of brain (Kaur et al., 
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2001); the latter exist as the resting form under normal conditions. However, under 
pathological conditions such as trauma, infection and hypoxia/ischemia, ramified 
microglia retract their processes and assume an amoeboidic form (Ling et al., 2001; 
Dheen et al., 2007). 
1.6.2 Properties of microglia 
AMC, which are multifunctional immune cells in the developing brain, play a 
key role in the cerebral innate immunity. Previous studies have reported that AMC are 
active macrophages in the developing CNS, scavenging cellular debris in pathological 
conditions and during normal development (Kaur et al. 2007). On the other hand, 
AMC in the developing brain may also execute a cytotoxic effect by the release of 
some toxic factors, including inflammatory mediators and NO in pathological 
conditions (Kaur et al. 2007). In addition to their predominant role in phagocytosis, 
recent studies have reported additional properties of AMC in the developmental 
period.  
1.6.2.1 Phagocytosis 
The phagocytic property of microglial cells has been proven by a large number 
of observations under various experimental methods such as uptake of exogenous 
substances, activated surface receptors and antigens associated with phagocytosis as 
well as the localization of hydrolytic enzymes (Kaur et al. 2007). Ultrastructural 
studies have shown the phagocytic nature of AMC in the normal neonatal brains or 
following Escheria coli (E coli) injection or hypoxic injury (Kaur and You, 2000; 
Kaur et al. 2004). The AMC in the PWM of the hypoxic developing brain participated 
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in the phagocytosis of apoptotic cells and degenerating axons (Kaur et al. 1985; Kaur 
and You, 2000; Kaur et al. 2006). In the fetal or neonatal rat brains, AMC were 
observed to devour apoptotic and necrotic cells following transient maternal hypoxia 
(Li, 1997). Further direct evidence of the phagocytic nature of AMC comes from their 
engagement in the phagocytosis of E coli injected directly into the postnatal rat brains 
(Kaur et al. 2004). Many E. coli were ingested by AMC in less than 3 h (Kaur et al. 
2004). Therefore, it appears from the above mentioned observations that a protective 
barrier formed by AMC is indispensable during the early development when the BBB 
is not fully functional.  
1.6.2.2 Antigen presentation 
Although the brain has been regarded as an ‘immune privileged’ organ for a long 
time, some studies showed that MHC I antigen expression was found on AMC (Ling 
et al. 1991). MHC antigens, which are cell surface molecules, are required for 
macrophages to activate T lymphocytes through presenting certain antigens to them. 
MHC I antigens serve as restriction elements for cytotoxic/suppressor lymphocytes. 
The expression of MHC I antigens on AMC also indicates that these cells are ready to 
interact with extravasating T lymphocytes when the BBB is deficient during the 
development (Kaur et al. 2007).  
The expression of MHC II antigens, which is required for macrophages to 
interact with helper/inducer T lymphocytes, is not found on AMC under physiological 
conditions. However, it is induced under experimental and pathological conditions 
(Kaur et al. 2004). For instance, the expression of these antigens is upregulated when 
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AMC are administered with interferon-γ (IFN-γ) or with lipopolysaccharide (LPS) 
(Xu et al. 1994, 1994). The AMC in the vicinity of injected live E coli are found to 
express MHC II antigens (Kaur et al. 2004; Kaur et al. 2007). The MHC II expression 
on AMC under pathological conditions demonstrates that AMC are able to interact 
with helper/inducer T lymphocytes to initiate an immune reaction.  
1.6.2.3 Proliferation 
One of the common features of microglial cell population is their remarkable 
capacity to increase their numbers when CNS injury or neurological disease processes 
occur (Ladeby et al. 2005). This expansion has been attributed predominantly to 
proliferation of activated microglia and, to a lesser extent, believed to be due to 
migration of microglia from neighboring brain areas (Ladeby et al. 2005). 
Proliferating microglia have been reported to be involved in the onset and/or 
progression of various CNS pathologies such as trauma (Urrea et al. 2007), 
hypoxia/ischemia (Denes et al. 2007), degenerative CNS diseases such as Parkinson’s 
disease (Henze et al. 2005) as well as Alzheimer's disease (AD) (Remington et al. 
2007). Micoglial proliferation induced by injury may also contribute to brain repair 
and functional recovery through phagocytosing the debris. However, excessive 
proliferation may also result in glial scar formation and produce cytotoxic factors 
(Byrnes and Faden 2007) 
Several molecules such as M-CSF, grannulocyte-macrophage colony stimulating 
factor (GM-CSF), interleukin-6 (IL-6) and, interleukin-3 (IL-3) have been 
demonstrated to be potent stimuli for microglia proliferation in vitro (Sawada et al. 
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1990). For all of these cytokines, microglia can express the corresponding receptors 
(Sawada et al. 1990). In addition, all of the cytokines mentioned above can be 
produced locally in the CNS (Schobitz et al. 1993). Therefore, under pathological 
conditions, microglia proliferation is induced by the cytokines mentioned above in an 
autocrine and/or paracrine fashion. Several in vivo studies using proliferating cell 
nuclear antigens such as Ki67, Bromodeoxyuridine (BrdU) and autoradiography have 
confirmed the hypothesis that microglia can proliferate in the developing brain 
(Schobitz et al. 1993). 
1.6.2.4 Migration 
It is well-known that microglia are capable of migrating toward damaged neural 
tissue to clear the debris at the injured site when necessary. Some researchers have 
reported that a rapid increase in number of microglial cells at injury sites is partly due 
to recruitment from blood monocytes or migration from other CNS regions 
(Brockhaus et al. 1996). The mechanism involving microglia migration to the injury 
sites is complex and poorly understood. The migration of microglia may be 
modulated by chemokines, which are released by microglia in an autocrine or 
paracrine manner during injury and infection (Zhou et al. 2007). Chemokine receptors 
may be redistributed to the cellular edge when microglia acquire a migratory 
phenotype (Zhou et al. 2007). The actin and tubulin, known as cytoskeleton proteins, 
are closely related with cellular morphology and migration. Under resting conditions 
in vitro, they are confined in the perinuclear region (Eugenin et al. 2005). However, 
when microglia are treated with a chemotactic stimulus, actin and tubulin are 
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rearranged to facilitate the process of attachment, protrusion and extension that 
contributes to migration of microglia (Eugenin et al. 2005). Chemokine orchestrated 
chemotaxis is regarded as a protective response to injury. However, the overmigration 
of microglia can also have harmful consequences by promoting toxicity (Eugenin et al. 
2005). 
1.6.2.5 Generation of reactive oxygen species (ROS) and nitrogen intermediates 
Microglia can generate ROS when activated by various stimuli such as hypoxia 
and LPS. Nicotinamide adenine dinucleotide phosphate (NADPH) oxidase, which is 
involved in the production of microglial-derived extracellular ROS (Babior 2000), is a 
pivotal enzyme which catalyses the generation of superoxide from oxygen. Except for 
the release of extracellular ROS, NADPH oxidase is also associated with microglial 
signaling pathway related to inflammatory response (Block and Hong 2007). NADPH 
oxidase-derived intracellular ROS may act as a second messenger to augment the 
inflammatory response through executing effects on transcription factor activation 
and kinase cascades (Block and Hong 2007). ROS can also strengthen the 
phagocytosis of microglia by supporting the degradation of ingested antigens and 
cellular debris (Block and Hong 2007). However, excessive intracellular ROS might 
cause microglial apoptosis. The overactivation of NADPH oxidase and the 
dysregulation of intracellular ROS in microglia have been reported to be associated 
with the pathogenesis of some CNS diseases, including AD (Shimohama et al. 2000) 
and PWMD (Haynes et al. 2005). 
NO, an important free radical, is released from L-arginine which is catalyzed by 
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nitric oxide synthase (NOS). NOS comprises of nNOS, eNOS and inducible NOS 
(iNOS).  Both nNOS and eNOS belong to constitutively expressed enzymes, which 
are activated by upregulated intracellular calcium. However, iNOS is 
calcium-independent, and NO produced by this enzyme is well documented to 
modulate immune activities. NO executes a large amount of physiologic functions, 
such as muscle relaxation, blood vessel dilatation, immune modulation as well as 
neuronal activity. NO directly interacts with guanylate cyclase, cytochrome P450, 
cyclooxygenase, and hemoglobin, to regulate their functions. In addition, NO can 
react with membrane lipids and induce lipid peroxidation. Indirectly, the combination 
of NO and superoxide can produce highly reactive intermediates, such as 
peroxynitrite, that can cause DNA strand breaks, lipid peroxidation, and protein 
nitration. In the postnatal brain, iNOS expression is not normally detected but can be 
found in activated microglia after inflammatory or hypoxic stimuli (Kaur et al. 2006a). 
Overproduction of NO derived from iNOS has been found to execute harmful effects 
on the oligodendrocytes and hence delayed myelination leading to the pathogenesis 
and development of PWMD in hypoxic rats (Kaur et al. 2006a). NO released from 
iNOS has also been reported to damage myelin-forming oligodendrocytes in 
neuropathological disorders such as multiple sclerosis (MS) and AD (Koprowski et al. 
1993). In vitro studies have demonstrated that activated microglial cell-derived NO 
induced the oligodendrocyte lysis (Merrill et al. 1993). Recent studies have also 
shown that peroxynitrite generated by iNOS in activated microglia may play a crucial 
role in the pathogenesis of PWMD as it is a highly reactive oxidant which is harmful 
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to the immature oligodendrocytes (Haynes et al. 2005; Li et al. 2005). 
1.6.2.6 Release of cytokines and chemokines  
A large number of cytokines and chemokines are usually expressed or secreted 
by microglia under pathological conditions. These cytokines and chemokines are 
implicated in microglial communication and effector network system with other types 
of cells (Hanisch 2002). Cytokines and chemokines secreted by microglia participate 
in innate defense mechanisms, help the initiation of immune responses, modulate the 
recruitment of leukocytes into the CNS and contribute to tissue repair and recovery 
(Hanisch 2002). 
1.6.2.6.1 TNF-α and its receptors 
TNF-α is one of the most important proinflammatory mediators released by 
activated microglia as well as blood-derived macrophages with pleiotropic functions 
during CNS inflammation (Arnett et al. 2001). In microglia culture, synthesis and 
release of TNF-α is induced by pathogens or pathogen components such as LPS and 
IFN-γ (Arnett et al. 2001). TNF-α can amplify CNS inflammatory response through 
inducing expression of chemokines and adhesion molecules in cerebrovascular 
endothelial cells and astrocytes, which help in recruitment of leukocytes into the CNS 
(Andrews et al. 1998). In addition, TNF-α is a multipotent inflammatory cytokine that 
initiates various responses such as apoptosis in some cells and proliferation in others 
through the activation of its different receptors (Andrews et al. 1998). Therefore, it is 
possible that TNF-α plays a wide variety of roles in PWM damage and repair.  
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All known effects of TNF-α occur through binding to one of two different 
receptors, known as TNF-R1 (p55) and TNF-R2 (p75), which are differentially 
expressed on various cell types in physiological and pathological conditions 
(Nakazawa et al. 2006b). The extracellular ligand-binding domains of TNF receptors 
show sequence homology containing cysteine-rich subdomains (Ledgerwood et al. 
1999). On the contrary, the intracellular domains of the two TNF receptors lack 
sequence homology, have no intrinsic enzyme activity, and transduce different 
biological signals through interaction with different intracellular protein complexes 
(Ledgerwood et al. 1999). The TNF-R1 contains death domain (DD), but TNF-R2 
doesn’t. The distinctions of TNF-R1 and TNF-R2 constitution lead to their diverse 
functions. In general, cell apoptosis and pro-inflammatory response are largely 
mediated through TNF-R1. Therefore, the activation of TNF-R1 is frequently 
associated with tissue or organ injury (Ledgerwood et al. 1999). The consequences of 
TNF-R2 activation are not fully known, but it is known to mediate cell proliferation 
and promote tissue repair and angiogenesis (Ledgerwood et al. 1999). 
TNF-R1, a typeⅠ transmembrane protein, has been found on most cells in the 
body. TNF-R1 is mainly stored in the Golgi apparatus in resting cells, from where it 
may be translocated to the cell membrane (Jones et al. 1999). Surface-expressed 
TNF-R1 contains a pre-ligand domain which locates within the cell membrane. The 
cytoplasmic domain of TNF-R1 is pre-bound to a cytoplasmic protein called silencer 
of death domain (SODD) (Jones et al. 1999). SODD can prevent the signal 
transduction of TNF-R1. After TNF binds to TNF-R1, SODD is released from the 
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binding complex. Subsequently, TNF-R1 binds to a distinct DD-containing 
cytoplasmic protein designated TNF-R-associated DD protein (TRADD) (Fig.A) 
(Jones et al. 1999). TRADD initiates two different signaling pathways namely 
programmed cell death (PCD) signaling pathway and phosphorylated c-Jun induced 
gene transcription by recruitment of distinct cytoplasmic adaptor proteins (Fig.A) 
(Jones et al. 1999). 
The PCD signaling pathway is initiated when the Fas-associated DD protein 
(FADD) binds to TRADD (Fig.A). Subsequently, pro-caspase-8 is recruited by the 
TRADD-FADD complex (Fig.A) (Chan et al. 2000). After this, pro-caspase-8 can be 
activated by autocatalytic process and release activated caspase-8 that may activate 
and cleave pro-caspase-3. Activated caspase-3 released from pro-caspase-3 results in 
cell apoptosis (Fig.A). TRADD initiates another signaling transduction by recruitment 
of two additional proteins namely receptor interacting protein-1 (RIP-1) as well as 
TNF-R-associated factor-2 (TRAF-2) (Chan et al. 2000). Subsequently, the 
TRADD-RIP-1-TRAF2 complex is internalized and released from TNF-R1. RIP-1 
regulates the recruitment of mitogen extracellular signal-regulated kinase (MEK) 
kinase-3 and transforming growth factor-beta (TGF-β)-activated kinase (TAK)1, 
which in turn, activates the β-subunit of the inhibitor of kB (IkB) kinase (IKK) 
complex (Fig.A) (Chan et al. 2000). This causes the phosphorylation of IkB protein. 
The phosphorylated IkB is degraded immediately and NF-kB is released from 
IkB-NFkB complex. NF-kB is phosphorylated, then enters the nucleus and initiates 
corresponding gene transcription (Fig.A) (Chen 2005). The TRADD-RIP-1-TRAF-2 
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complex can also activate and phosphorylate c-Jun N-terminal kinases (JNKs) and 
p38 MAPKs through MEKs cascades (Fig.A) (Chen 2005). Subsequently, 
phosphorylated JNK activate and phosphorylate c-Jun, a subunit of the transcription 
factor activating protein 1 (AP-1) (Fig.A) (Ichijo et al. 1997). Phosphorylated c-Jun 
translocates to nucleus and activates gene transcription (Fig.A). TNF-R1 can also 
activate sphingomyelinase (SMase) enzyme through interaction with FAN (factor 
associated with neutral SMase activation). Activated SMase can breakdown plasma 
membrane sphingomyelin which result in the generation of ceramide (Ichijo et al. 
1997). Ceramide is a signal that induces cell apoptosis through the mitochondrial 
pathway. TNF-R1 can also activate the phosphatidylinositol-3 kinase (PI3K) and 
ras-raf-MEK1-ERK1, 2 pathway, which cause Akt signaling pathway cascades (Ichijo 
et al. 1997). Akt and ERK-1,-2 are involved in cell proliferation and survival (Ichijo 
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Figure A. Signaling pathways leading to the main cellular responses of TNF-α 
through TNF-R1. TNF-α binds to TNF-R1 and, hence, activates MAP kinase, NF-kB 
as well as cellular apoptosis signaling pathways. 
The role of TNF-R2 in physiological and pathological processes is less 
investigated. Unlike TNF-R1, TNF-R2 can not recruit apoptosis associated proteins 
such as TRADD and FADD because of lack of an intracellular DD (Ichijo et al. 1997; 
Rothe et al. 1994). Therefore, the activation of TNF-R2 doesn’t trigger cellular 
apoptosis. However, some research has demonstrated that expression of TNF-R2 on 
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the cell potentiates TNF-R1-induced death through the formation of p55 and p75 TNF 
receptors heterocomplexes (Rothe et al. 1994). Furthermore, TNF-α induces a 
conformational change in TNF-R2 which activates endothelial/epithelial tyrosine 
kinase (Etk) in a TRAF2-independent manner (Rothe et al. 1994). The 
phosphorylation of Etk causes Akt activation, which contributes to TNF-induced cell 
proliferation (Rothe et al. 1994). 
1.6.2.6.2 Interleukin 1 (IL-1) and its receptors 
IL-1 includes two mediators, IL-1α and IL-1β, which share similar biological 
activities and three-dimensional structure but have less than 30% sequence homology 
(Grehan et al. 1997). The role of IL-1 is modulated through binding to distinct 
receptorss including a true receptor (IL-1RⅠ), a decoy (IL-1RⅡ) as well as a specific 
receptor antagonist (IL-1ra) (Grehan et al. 1997). Although IL-1α and IL-1β can bind 
equally to type Ⅰand typeⅡIL-1R, signal transduction across the plasma membrane 
has been reported to be accomplished via the type Ⅰreceptor (Grehan et al. 1997). At 
present, there is no evidence that a signal can be transmitted through the type Ⅱ 
receptor. In the CNS, high level expression of IL-1 is found in the prenatal and 
postnatal period, and its expression declines gradually to low constitutive levels in the 
adult and increases markedly after injury (Vela et al. 2002). Astroglia and microglia 
possess IL-1 receptors and are the predominant intrinsic sources of IL-1 in the CNS, 
but oligodendroglial cells also produce IL-1 and express IL-1 receptors (Vela et al. 
2002). IL-1 induces activation and secretion of multiple factors by microglia and 
astrocytes. It has been reported recently that remyelination is dramatically reduced in 
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the absence of IL-1β, but the effects of this cytokine on cells of the oligodendroglial 
lineage remain to be elucidated (Vela et al. 2002).                             
1.6.2.6.3 Macrophage-colony stimulating factor  
The macrophage-colony stimulating factor (M-CSF), also designated as CSF-1, 
is a hematopoietic cytokine that induces activation, proliferation, and migration of 
microglia and is released mainly by macrophages, T cells, B cells and microglia 
(Stanley et al. 1997). M-CSF has also been well known as an important inflammatory 
mediator and may modulate the production of proinflammatory cytokines from 
macrophages (Hao et al. 2002). M-CSF executes its pleiotropic effects through 
binding to its high-affinity receptor CSF-1R that is encoded by the c-Fms 
proto-oncogene (Rovida et al. 2008). 
1.6.2.6.4 Monocyte chemoattractant protein-1  
Chemokines are chemotactic cytokines which act by binding to their respective 
G-protein-coupled receptors. Chemokines may contribute to the migration of 
microglia to injured CNS sites and potentiate their activation. In addition, chemokines 
released by microglia are likely to induce leukocyte migration and amplify the CNS 
inflammatory response. Together with integrins and endothelial cell-adhesion 
molecules, chemokines are believed to regulate the migration of macrophages, 
leukocytes and other immune cells (Ambrosini and Aloisi 2004). A variety of 
inflammatory chemokines and their respective receptors have been found in the brain 
during development and disease processes. Glial cells, stimulated by LPS and some 
proinflammatory cytokines such as TNF-α and IL-1 in vitro have been shown to 
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generate several chemokines such as Monocyte chemoattractant protein-1 (MCP-1), 
interleukin-8 (IL-8), macrophage inflammatory protein 1 alpha (MIP-1α) as well as 
macrophage inflammatory protein 1 beta (MIP-1β) (Ehrlich et al. 1998; Lipovsky et 
al. 1998; Lokensgard et al. 1997; McManus et al. 1998; Peterson et al. 1997). 
Microglia in vitro can also express chemokine receptors such as chemokine (C-X3-C 
motif) receptor 1 (CX3CR1) (Nishiyori et al. 1998), chemokine (C-C motif) receptor 
3 (CCR3), chemokine (C-X-C motif) receptor 4 (CXCR4) (Lavi et al. 1997) and 
chemokine (C-C motif) receptor 5 (CCR5) (He et al. 1997).   
Among chemokines, MCP-1, also designated as CCL2, is a member of 
β-chemokine subfamily, which modulates the migration of lymphocytes, microglia 
and monocytes to the inflammation sites in the CNS (Cross and Woodroofe 1999; 
Taub et al. 1995; Gunn et al. 1997; Babcock et al. 2003). MCP-1 exerts its effects on 
target cells through interaction with its receptor, chemokine (C-C motif) receptor 2 
(CCR2) which is a seven-transmembrane domain G-protein coupled receptor. It is 
produced predominantly by microglia and astrocytes in the CNS (Hayashi et al. 1995). 
The expression of MCP-1 and CCR2 has been found to be upregulated following 
various CNS insults such as AD (Fenoglio et al. 2004), ischemia (Che et al. 2001; 
Minami and Satoh 2003; Vilhardt 2005), MS and its animal model experimental 
autoimmune encephalomyelitis (EAE) (Sorensen et al. 1999; Simpson et al. 1998; 
Glabinski et al. 2003), and HIV type-1-associated dementia (Conant et al. 1998),. In 
EAE animal model, MCP-1 resulted in the activation and migration of endogenous 
microglia and blood-derived macrophages to demyelinated sites, potentiating myelin 
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phagocytosis (Ambrosini and Aloisi 2004). Furthermore, the functional antagonism of 
MCP-1 may attenuate leukocyte extravasation and decrease the severity of CNS 
injury (Calvo et al. 1996; Muessel et al. 2002). In a murine stroke model, MCP-1 
deficiency has been demonstrated to play a protective role in acute infarct 
development (Hughes et al. 2002). It has also been reported that MCP-1 could 
potentially modulate microglial activation and induce migration of blood-derived 
monocytes into the brain in hypoxic-ischemic neonatal rats (Ivacko et al. 1997). 
1.7 Aims of this study 
Inflammation has been recognized as a major factor leading to PWMD (Kadhim 
et al. 2002; Wu and Colford, Jr. 2000) under hypoxic conditions. It is well 
documented that microglial cells, the resident immune cells of the CNS, and 
astrocytes play a crucial role in the modulation of inflammatory response in some 
diseases (Dheen et al. 2005b; Vilhardt 2005). In the developing brain, AMC 
aggregate in large numbers in the PWM (Ling and Wong 1993). The activated 
microglia may release a lot of potentially cytotoxic molecules such as 
proinflammatory mediators, ROS, proteinases and complement proteins. However, 
the role of AMC and astrocytes in PWMD in neonatal brain under hypoxic conditions 
has not been fully elucidated. The main aim of this study was to determine if AMC 
and astrocytes contribute to PWMD under hypoxic conditions in the neonatal brain. 
The potential mechanisms and signaling pathways by which activated AMC and 




1.7.1. Role of AMC in the PWMD 
A large number of proinflammatory mediators such as TNF-α, IL-1β, MCP-1 and 
M-CSF are usually expressed or secreted by microglia under inflammatory conditions. 
Activated microglial cells communicate or cross talk with other type cell through 
these cytokines and chemokines. As mentioned earlier, TNF-α executes different 
functions through binding to one of two different receptors, TNFR1 (p55) and TNFR2 
(p75). TNF-α induces cell apoptosis and mediates pro-inflammatory response through 
TNFR1. The action of IL-1 is modulated by two different types, IL-1RⅠ and 
IL-1RⅡ. 
Based on these data, it is hypothesized that AMC in the PWM may induce 
oligodendrocyte and axon damage through expression of proinflammatory cytokines 
and chemokines such as,TNF-α, IL-1β, MCP-1 and M-CSF in hypoxic neonatal rats. 
To address this,  
1). The mRNA and protein expression of cytokines such as TNF-α, IL-1β, MCP-1 
and M-CSF in AMC in the PWM was examined.  
2). The signaling pathway involved in production of some of the cytokines such as 
TNF-α and IL-1β in hypoxic conditions was also examined. 
3). It was then ascertained whether developing oligodendrocytes in the PWM in 
hypoxic neonatal rats would be the potential target of TNF-α and IL-1β by 
expressing TNF-R1 and IL-1R1 and, if so, whether they would undergo apoptosis 
or necrosis and a significant reduction in the number. 
4). The expression of TNF-R1 and IL-1R1 on the axons was also examined. 
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5). Changes in the axons and myelination disturbances were investigated. 
1.7.2. Regulation of microglial migration in the PWM by MCP-1 production by 
AMC in hypoxia 
In the CNS, microglia appear to be the main source for the generation of 
chemokines including interferon-gamma-inducible protein-10 (IP-10) and MCP-1 
(Gebicke-Haerter et al. 2001). MCP-1 is well documented to play a significant role in 
the initiation and progression of acute inflammatory brain injury in the neonatal rat 
(Galasso et al. 2000). It has been reported that MCP-1 could activate and recruit 
macrophages within inflammatory foci to aggravate CNS injury (Galasso et al. 2000). 
It has also been found that MCP-1 and its receptor is colocalized in the microglial 
cells (Galasso et al. 2000). Therefore, it is possible that MCP-1 may activate and 
direct microglia recruitment to injured CNS sites in an auto- and paracrine manner 
and thus amplify the ongoing inflammatory response. In view of the above, MCP-1 
released by AMC under hypoxic conditions may contribute to the migration of AMC 
from the surrounding brain areas such as the cerebral cortex or it may attract 
infiltration of monocytes to the PWM and aggravate PWMD. To address this, 
1). Cell count of AMC and their proliferation rate in the PWM in hypoxic rats was 
examined. 
2). The mRNA and protein expression of MCP-1 and CCR2 in AMC in the PWM 
at different time points in control and hypoxic rats was observed. 
3). The migration of AMC to the PWM was induced by MCP-1 injection in vivo.  
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4). MCP-1 production via activation of NF-kappaB signaling pathway in the 
activated microglia under hypoxic conditions in vitro was investigated.  
5). The in vitro migration of microglia in response to microglia conditioned 
medium was also assessed.  
1.7.3. Regulation of TNF-α and IL-1β generation by astrocytes in the PWM by 
AMC-derived M-CSF in hypoxic neonatal rats  
It has been reported that besides microglial cells, astrocytes may also contribute 
to an inflammatory response by releasing inflammatory cytokines (Sawada et al. 
1995). Astrocytes have been thought to be predominantly responsible for the release 
of inflammatory mediators in the late phase of inflammatory response in the CNS 
(Sawada et al. 1995). Therefore, it was speculated that astrocytes may also be another 
source of TNF-α and IL-1β production in the PWM resulting in damage to the axons 
and oligodendrocytes. However, the mechanism by which astrocytes are activated and 
release proinflammatory cytokines has not been fully elucidated. Recent studies have 
shown that M-CSF is an important inflammatory mediator and can also promote the 
release of proinflammatory cytokines from immune cells by binding to its receptor, 
CSF-1R (Hao et al. 2002; Rovida et al. 2008). 
Arising from the above, we hypothesized that M-CSF produced by AMC in the 
early phase following hypoxic injury may activate astrocytes and regulate the release 
of TNF-α and IL-1β in the later phase by them that may sustain and exacerbate the 
inflammatory response in hypoxic neonatal rats. To address this,  




2). The expression of CSF-1R, TNF-α, IL-1β in astrocytes in the PWM in hypoxic     
rats was examined. 
3). It was then ascertained whether M-CSF protein can induce the expression of 
CSF-1R and production of TNF-α and IL-1β from primary cultured astrocytes 
through MAP kinase signaling pathway in vitro. 
This research mainly focuses on the mechanisms by which microglia and 
astroglia induce oligodendrocyte and axon damage in the PWM in hypoxic neonatal 
rats. The findings obtained may be helpful in understanding the role of these cells in 
the pathogenesis of PWMD in hypoxic conditions and also for development of better 































Materials and Methods 
2.1 Animals 
Wistar rats (1-day old) were used in this study as the developmental stage of 
white matter in rats at birth has been described to be equivalent to mid-gestation in 
humans (Sheldon et al. 1996). 222 rats were subjected to hypoxia by placing them 
in a chamber filled with a gas mixture of 5 % oxygen and the remainder 95% 
nitrogen (Model: MCO 18M; Sanyo Biomedical Electrical Co, Ltd, Tokyo, 
Japan.). The rats were then allowed to recover under normoxic conditions for 
3 and 24 h, 3, 7 or 14 days before being killed. Another group of 222 rats kept 
outside the chamber were used as age-matched controls (Table 1). For mixed 
primary glial cell culture, another 160 rat pups were used. Animal handling and 
experiments were approved by Institutional Animal Care and Use Committee, 
National University of Singapore (NUS). 
Table 1.  Number of rats killed at various time points after the hypoxic exposure 
(in brackets) and their age-matched controls for various methods (outside the 
brackets). 
Control ( hypoxia)    Double                  Real time-       ELISA and       MCP-1      Electron  
                   Immunohistochemistry     RT-PCR      Western blotting    Injection    microscopy 
1 day ( 3h )             9 (9)                    15 (15)           15 (15)                        3(3) 
2 days ( 24h )           9 (9)                    15 (15)           15 (15 )                        3(3) 
4 days ( 3days )         9 (9)                   15 (15)            15 (15)                         3(3) 
8 days ( 7days )         9 (9)                   15 (15)            15 (15)            24           3(3) 
15 days ( 14 days )      9 (9)                   15 (15)             15 (15)                         3(3) 
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2.2 Mixed Glial Cell Culture   
2.2.1. Materials 
Dulbecco's Modified Eagle Medium (DMEM) (Sigma, USA, Cat. No. 
D1152) 
Insulin (Sigma-Aldrich, USA, Cat. No. I0516) 
Non-essential amino acid (Sigma, USA, Cat. No. M7145)  
Antibiotic antimycotic solution (100X Sigma-Aldrich, USA, Cat.No. 
A5955) 
Trypsin and ethylenediaminetetraacetic acid (EDTA) (10X Sigma, USA, 
Cat. No. T4549) 
Ethylenediaminetetraacetic acid (EDTA) (10X Sigma, USA, Cat. No. 
E-7889) 
Deoxyribonuclease Ⅰ (Sigma-Aldrich, USA, Cat.No. D4527) 
Fetal bovine serum (FBS) (Invitrogen, USA, Cat. No. 10099)   
70µm nylon cell strainer (BD Biosciences, USA, Cat. No. 352350) 
75cm2 tissue culture flasks (NUNC, Denmark) 
Lectin (Lycopersicon esculentum tomato) (Sigma-Aldrich, USA, Cat. No.    
L0401 ) 
4’, 6- diamidino-2-phenylindole dihydrochloride (DAPI) (Sigma, USA, 
Cat. No. D1306) 
Phosphate buffered saline (PBS; 0.1M, pH 7.4) 
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2.2.2. Procedure   
2.2.2.1. Removal of Brain Tissue 
The rat pups were deeply anesthetized with 6% sodium pentobarbital 
(60mg/kg) and were decapitated. The heads were wiped with 70% ethanol and 
washed with ice-cold PBS. The skin was incised along the midline in a caudal to 
rostral direction to expose the skull. The skull was penetrated with the tip of a pair 
of scissors and cut-opened rostrally to the nose. Further from the original point of 
incision, the skull was cut mediolaterally and then in a rostral direction reaching 
the first set of cuts. In this way, two roughly rectangular flaps of skull were 
removed. Underlying brain tissue was moistened with PBS. A pair of curved 
forceps was used to scoop the brain tissue out. Then, the brain tissue was placed 
onto a 100 mm diameter dish with PBS and was rinsed three times. The cortices 
were collected into a 50 ml tube in PBS on ice and were rinsed three times with 
PBS. The undesired brain regions, such as thalamus, hippocampus, basal ganglia, 
and, olfactory bulb, were removed first. The meninges and superficial vessels 
were removed subsequently. The remaining cortices were transferred to a new 60 
mm diameter dish, containing cold PBS. The tissue was finely dissected further to 
remove the remaining meninges and vasculature. Finally, the tissue was transfered 
to a new 60-mm-diameter dish containing 9 ml cold DMEM medium. 
2.2.2.2. Mechanical dissociation of brain tissue 
A long pair of scissors was used to chop the brain tissue in the dish with 
gentle up-and-down motion. The tissue pieces were collected and mechanically 
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dissociated by pipetting in and out with a 10ml plastic pipette in a 50 ml sterile 
concial tube on ice. 
2.2.2.3. Enzymatic digestion 
One ml of Trypsin-EDTA solution (0.5mg/ml) and 100μl of 
Deoxyribonuclease Ⅰsolution (50μg/ml) were added into the tube, and mixed 
before the solution was transfered to a 75cm2 tissue culture flask. The flask was 
placed in an orbital shaker at 37℃ and shaken at 200 rpm/min for 15 min. Cells 
were passed through a 70μm cell strainer to remove remaining clumps of tissue 
and then transfered to a 50ml centrifuge tube again.  
Finally the cell suspension was centrifuged at 1000rpm for 5 min, then 
seeded in culture dish containing DMEM plus 10% FBS at a density of 1.2×106 
cells/ml and cultured at 37℃ in humidified 5% CO2/95% air. Medium was 
changed every 2-3 days and confluency was achieved after 10 to 12 days in vitro.  
2.2.3. Microglia purification 
Microglial cultures were prepared by a mild trypsinization method as 
described by Saura and others (Saura et al. 2003). The mixed glial cultures were 
purified after 10 to 12 days. Briefly, the cultures were washed with PBS twice and 
incubated with a trypsin solution (1ml of 0.25% trypsin and 20μl of 0.5M EDTA 
diluted in 40 ml of DMEM) for about 10 min. This resulted in the detachment of 
an upper layer of cells which were removed subsequently. The microglial cells 
remained attached to the bottom of the flask and were cultured in DMEM 
contained 10% FBS.  
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For enzyme-linked immunosorbent assay (ELISA), 2.5×105 cells were seeded 
per well in 24-well plates. For immunoblotting and RNA extraction, 1×106 cells 
were seeded per 75cm2 flask. For immunocytochemistry, 2.5×105 cells were 
seeded per well in a 24 multi-well plate and incubated at 37°C in a humidified 
incubator supplemented with 95% air and 5% CO2 for 24h. The following day, the 
cells were subjected to different treatments.   
The purity of microglia was determined immunohistochemically using Lectin 
(1:100), a marker for microglia, and DAPI (20μg/ml) a nuclear marker of all cells 
attached to the coverslips. The purity of microglial cultures was found to be 
around 96%. 
2.2.4. Astrocytes purification 
The mixed glial cultures were purified after 12 to 14 days. The flask 
containing the mixed glial cells was shaken for 15h at 200rpm. Non-astroglial 
cells including microglial cells and oligodendrocytes in the supernatant were 
removed after shaking (Kliot et al. 1990; McCarthy and de 1980; Rovida et al. 
2008). The majority of the remaining cells were astrocytes. The astrocytes 
remained attached to the bottom of the flask and were cultured in DMEM 
supplemented with 10% FBS.  
For immunoblotting and RNA extraction, 1×106 cells were seeded per 75cm2 
flask. For immunocytochemistry, 2.5×105 cells were seeded per well on a 24 
multi-well plate and incubated at 37°C in a humidified incubator supplemented 
with 95% air and 5% CO2 for 24h.  
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The purity of astrocyte cultures was assessed by double 
immunocytochemistry analysis of cultured cells with mouse anti-GFAP (1:1000: 
Chemicon International, CA, USA), a widely used marker for astrocytes, and 
DAPI (20μg/ml; Sigma), a nuclear marker of all cells. This double-labeling 
analysis showed that more than 99% of the confluent cells were GFAP-positive 
astrocytes. 
2.3 Treatment of microglial cells for expression of TNF-α, IL-1β, M-CSF and 
MCP-1 
Microglial cell cultures were divided into seven groups: Group Ⅰ: To study 
the effects of hypoxia on expression of TNF-α and IL-1β in microglial cells. For 
this, the cells were exposed in a hypoxia chamber (Model 18M; Multi-gas 
incubator, Sanyo Company Pte Ltd, Japan) for 1, 2, 4 and 6h at 3% oxygen, 5% 
CO2 and 37℃. Group Ⅱ: To study the effects of hypoxia on MAP kinase pathway. 
In this, the microglial cells were placed in a hypoxia chamber for 0.5, 1, 2 and 4h 
at 3% oxygen, 5% CO2 and 37℃. Group Ⅲ: To examine the effects of MAP 
kinase inhibitors on hypoxia-induced TNF-α and IL-1β expression in microglial 
cells. Microglial cell cultures were treated with either SP600125 (1μM; Scientific, 
Inc, USA) or SB203580 (1 μM; MERCK, Darmstadt, Germany), inhibitors of 
JNK and p38, respectively, 30 min before hypoxia treatment. Group Ⅳ: To study 
the effects of hypoxia on expression of M-CSF in microglial cells, the cells were 
exposed to hypoxia in a chamber for 1, 2, 4 and 6h at 3% oxygen, 5% CO2 at 37℃. 
Group Ⅴ: To study the effects of hypoxia on release of MCP-1 and expression of 
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MCP-1 mRNA in microglial cells. For this, the cells were exposed to hypoxia in a 
chamber for 1, 2, 4 and 6h at 3% oxygen and 5% CO2 and at 37℃. Subsequently, 
the microglial cells were used for mRNA extraction and the medium was collected 
and stored at −20°C for ELISA. Group Ⅵ: To study the effects of hypoxia on 
NF-kappaB signaling pathway. In this, the microglial cells were placed in a 
hypoxia chamber for 15, 30min, 1 and 2h or hypoxia + BAY 11-7082 (10mM; 
Calbiochem, CA, USA) for 4h at 3% oxygen and 5% CO2 at 37℃. Subsequently, 
the protein was extracted from the microglial cells and stored at −20°C for 
Western blotting. Group Ⅶ: To examine the effects of the medium derived from 
hypoxia-treated microglial cultures on chemotaxis of microglia in vitro. In the 
latter, the cells were exposed in a hypoxia chamber for 4h at 3% oxygen and 5% 
CO2 at 37℃. Subsequently, the medium was collected and stored at −20°C for 
chemotaxis assay. In all the experiments, microglial cells in matching controls 
were incubated in incubator with 95% air and 5% CO2 at 37°C.  
2.4 Treatment of Astrocytes Culture 
Astrocyte cultures were divided into three groups: Group Ⅰ: To study the 
effects of M-CSF treatment on expression of TNF-α, IL-1β and CSF-1R in the 
astrocytes. The cells were treated with M-CSF (Antigenix America Inc; Cat. No. 
RC333140; 25ng/ml) for 3, 6, 12 and 24h at 37°C in a humidified incubator 
supplemented with 95% air and 5% CO2 at 37℃. Group Ⅱ: To study the effects 
of M-CSF treatment on MAP kinase pathway. In this, the astrocytes were treated 
with M-CSF (Antigenix America Inc; Cat. No. RC333140; 25ng/ml) for 15, 
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30min, 1 and 2h at 95% air, 5% CO2 at 37℃. Group Ⅲ: To examine the effects of 
MAP kinase inhibitors on M-CSF treatment-induced TNF-α and IL-1β expression 
in the astrocytes. Astrocyte cultures were treated with either 1μM SP600125 
(Scientific, Inc, USA) or 1 μM SB203580 (MERCK, Darmstadt, Germany), 
inhibitors of JNK and p38, respectively, 30 min before M-CSF administration. In 
all the experiments, astrocytes in matching controls were incubated in an 
incubator filled with 95% air and 5% CO2 at 37°C. 
2.5. RNA Isolation and Real time reverse transcription-polymerase chain 
reaction (RT-PCR) 
2.5.1. Materials 
     RNeasy mini kit (Qiagen, Germany, Cat. No. 74106) 
Molony murine leukemia virus reverse transcriptase (M-MLV) (Promega, 
USA, Cat. No. M1701) 
Oligo(dT) primer (Promega, USA , Cat. No. C1101) 
dNTP mix (Promega, USA , Cat. No. U1240) 
RNase inhibitor (Promega, USA, Cat. No. N2111,) 
LightCycler FastStart DNA MasterPLUS SYBR Green I (Roche Applied 
Sciences, Germany, Cat. No. 03515885001) 
TAE buffer (Invitrogen, USA, Cat. No. 15558034) 
100bp DNA step ladder (Promega, USA, Cat. No. G6951) 
LightCycler instrument (Roche Molecular Biochemicals) 
GeneGenius (Syngene, UK) 
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Spectrophotometer (Eppendorf, Germany) 
2.5.2 Procedure 
2.5.2.1 Extraction of total RNA 
The PWM was dissected under the Leica stereo microscope (MZ 6; Leica Pte 
Ltd, Singapore). Total RNA was extracted from the PWM or cultured microglial 
cells or cultured astrocytes using RNeasy mini kit (Qiagen, Valencia, CA, USA) 
according to the manufacturer's protocol. Approximately, 20g tissues or 1×106 
cells were used to extract the total RNA. Tissues or cells were lysed in 650μl of 
RLT buffer (containing a highly denatured guanidine isothiocyanate which 
inactivates RNase). The cells then were scraped from the flask with the scraper. 
The lysate was homogenized, then centrifuged for 30s at 14000×g in a microfuge 
and the supernatant was mixed with 650μl of 70% ethanol to clear lysate. The 
sample was applied to an RNeasy mini spin column (silica-gel membrane, 
maximum binding capacity is 100μg of RNA longer than 200 bases) and spun for 
30sec at 14000×g and then flow-through was discarded. The RNA bound to the 
membrane was washed with buffer RW1 and RPE sequentially. High-quality RNA 
was then eluted in 20μl of RNase free water. The concentration and purity of the 
extracted RNA was evaluated spectrophotometrically at 260 and 280 nm 
(Biophotometer, Eppendorf, Germany) 
2.5.2.2 cDNA Synthesis 
The cDNA synthesis was carried out in a total volume of 25μl containing the 
RNA template, Oligo(dT) Primer, M-MLV reverse transcriptase, transcription 
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buffer, dNTP, RNase inhibitor and RNase-free water. 
2μg of RNA was added with 1μl Oligo (dT)15 primer into a microcentrifuge 
tube and then heated to 70° for 5 min to melt secondary structure within the 
template. The tube was immediately transferred to ice. The following components 
were added to the annealed primer/template in the order shown. 
              M-MLV 5 X Reaction Buffer        5μl 
              10 X dNTP Mix                  1.25μl 
              RNase inhibitor                  0.675μl    
              M-MLV Reverse transcriptase       1μl  
              RNase free water to final volume     25μl 
   The reaction mixture was mixed gently and incubated for 1h at 42℃. Finally 
the reaction was terminated by heating at 95℃ for 5min. The cDNA synthesized 
was kept at 4℃. 
2.5.2.3 Real time RT-PCR  
Quantitative RT-PCR was carried out on a Light Cycler 3 instrument using a 
FastStart DNA Master plus SYBR Green I kit (Roche Diagnostics, GmbH, Roche 
Applied Science, Germany) according to the manufacturer's instructions. Briefly, a 
light-cycler master mix was prepared using 2 µL Light Cycler-FastStart DNA 
Master plus SYBR Green I with forward and reverse primers for TNF-α, IL-1β, 
TNF-R1, IL-1R1, M-CSF, CSF-1R, MCP-1, CCR2 and β-actin (Table 2.) at a final 
concentration of 0.5 µM each. A 2 µL sample of the cDNA was added into 18 µL 
of LightCycler master mix and transferred into LightCycler glass capillaries. The 
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capillaries were capped, placed in a LightCycler carousel and centrifuged in a 
specific LightCycler centrifuge. Thermal cycling was carried out. The first 
segment of the amplification cycle consisted of a denaturation programme at 95°C 
for 10 min. The second segment was performed as follows: 35 cycles of 
denaturation at 95°C for 15s, annealing at 60°C (for TNF-α, IL-1β, TNF-R1, 
IL-1R1, M-CSF, CSF-1R, MCP-1 and CCR2) or 62°C (for β-actin) for 5s, and 
elongation at 72°C for PCR product size per 25s. The third segment consisted of a 
melting curve programme. The final segment consisted of a cooling programme at 
40°C. The expression level of each gene was quantified, expressed as Ct, the cycle 
number at which the LightCycler system detected the upstroke of the exponential 
phase of PCR product accumulation, and normalized by the level of expression of 
β-actin in each individual sample. The mRNA expression levels of various genes 
studied in the experimental groups and control groups were compared using the 
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Table 2 Sequence of specific primers 
Primer               Forward          Reverse          Amplicon size 
TNF-α          caacaaggaggagaagttcc   ctctgcttggtggtttgctac        134bp 
                     
IL-1β           ggaacccgtgtcttcctaaag    ctgacttggcagaggacaaag     123bp 
                  
TNF-R1         ggcccacttctaatgtgtgaa    aggctacaagagggagacagc     163bp 
                       
IL-1R1          taaacctctgcctcttgacga    tgcttcccctggtatgtgtag        146bp 
M-CSF        agagctcctgcctaccaagac     tcctaaaggaaagggtcctga      195bp 
CSF-1R        ggagatcttctcgcttggtct      ggaaggtgggtcttctggtag       173bp 
MCP-1         tctcttcctccaccactatgca    ggctgagacagcacgtggat         91bp 
CCR2               cgcagagttgacaagttgtg     gccatggatgaactgaggta         233bp        
β-actin        tcatgaagtgtgacgttgacatccgt  cctagaagcatttgcggtgcaggatg    285bp 
 
2.5.2.4 Detection of PCR product 
   PCR products were run on agarose gel using electrophoresis. 1.5% agarose gel 
was prepared by heating agarose in the TAE buffer. 5% of ethidum bromide was 
added into the gel and the gel was cooled, poured onto a gel tray and allowed to 
solidify. 10μl of each real time PCR product was loaded in each lane of the gel 
and electrophoresed at 110V for 45min in TAE buffer with 10μl of 100bp DNA 
ladder. The PCR products in gel were visualized with an ultraviolet 
trans-illuminator and photographed. The 100bp DNA ladder was used to 
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2.6. Western Blotting 
2.6.1. Materials 
Protease inhibitor cocktail kit (Pierce, USA, Cat. No. 78410) 
Tissue protein extraction reagent (Pierce, USA, Cat. No. 78503) 
Mammalian protein extraction reagent (Pierce, USA, Cat. No. 78503) 
Protein assay kit (Bio-Rad, USA, Cat. No. 5000002) 
Bovine serum albumin (BSA) (Bio-Rad, USA, Cat. No. #500-0007) 
10% resolving gel: 
H2O                      7.9ml 
  30% acrylamide mix                   6.7ml 
1.5 M Tris (pH 8.8)                   5.0ml 
  10% sodium dodecyl sulphate (SDS)     0.2ml 
  10% ammonium persulfate                 0.2ml     
  TEMED                   0.008ml 
5% stacking gel: 
H2O                      5.5ml 
  30% acrylamide mix                   1.3ml 
1.0 M Tris (pH 6.8)                   1.0ml 
  10% SDS                    0.08ml 
  10% ammonium persulfate                0.08ml 
  TEMED                   0.008ml 
1x SDS gel-loading buffer: 
50mM Tris.Cl (pH 6.8) 
  100mM dithiothreitol 
  2% SDS 
  0.1% bromophenol blue 
  10% glycerol 
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Tris-glycine electrophoresis buffer: 
25mM Tris 
  250mM glycine 
  0.1% SDS 
Transfer buffer: 
25mM Tris 
  250mM glycine 
  20% Methanol 
1X Tris-buffered saline (TBS): 
  Tris base   2.42 g 
  NaCl    0.8 g 
  H2O up to 1 liter; adjusted to pH 7.6 with 2N HCl 
1X Tris-buffered saline tween (TBST): 
  1X TBS 1 liter 
  0.1% Tween 20 












Materials and Methods 
Table 3 All antibodies used in experiments 
Antibody         Host           Company          Cat. NO.  Concentration 
TNF-α           rabbit       Chemicon, USA          AB1837P      1:1000     
IL-1β            rabbit       Chemicon, USA          AB1832P     1:5000     
TNF-R1          rabbit       Santa Cruz, USA          sc-7895       1:500     
IL-1R1           rabbit       Santa Cruz, USA          sc-689         1:500 
M-CSF          rabbit       Santa Cruz, USA          sc-13103       1:200 
CSF-1R          rabbit      Santa Cruz, USA           sc-692         1:500 
MCP-1          goat        Santa Cruz, USA           sc-1785       1:100 
CC1             mouse      Oncogene, USA             OP80         1:20 
CCR2            goat        Santa Cruz, USA          sc-31563        1:200 
GFAP            mouse      Chemicon, USA             MAB360     1:1000 
phospho-c-Jun    rabbit    Cell Signaling Technology, USA      9164s     1:500 
c-Jun            rabbit    Cell Signaling Technology, USA      9162     1:500 
phospho-JNK     rabbit    Cell Signaling Technology, USA      9251s     1:500 
JNK            rabbit     Cell Signaling Technology, USA      9252      1:500 
phospho-p38     rabbit    Cell Signaling Technology, USA       9211s      1:500 
p38             rabbit    Cell Signaling Technology, USA       9212      1:500 
phospho-ERK1/2  rabbit    Cell Signaling Technology, USA       9101s      1:500 
ERK1/2          rabbit    Cell Signaling Technology, USA       9102      1:500 
phospho-NF-kappaB  rabbit   Santa Cruz, USA                 sc-109     1:200 
NF-kappaB       rabbit    Cell Signaling Technology, USA      3031S     1:500 
phosph-IkappaB  rabbit     Cell Signaling Technology, USA       9241S     1:500 
IkappaB         rabbit    Cell Signaling Technology, USA      9242      1:500 
Myelin basic protein (MBP)  goat  Santa Cruz, USA             sc-13912   1:1000 
Neurofilament (NF-200)  mouse  Sigma-Aldrich, USA            N0142     1:1000 
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Goat anti-rabbit IgG conjugated with horseradish peroxidase (Cell Signaling 
Technology, USA, Cat. No. 7074)  
Goat anti-mouse IgG conjugated with horseradish peroxidase (Pierce, USA, Cat. 
No. 31430,) 
Stripping buffer (Pierce, USA, Cat. No. 0021059) 
2.6.2. Procedure 
The PWM was dissected under the Leica stereo microscope (MZ 6; Leica Pte 
Ltd, Singapore). Proteins were extracted from the PWM or microglial cells or 
astrocytes using protein extraction kit according to the manufacturer's protocol. 
Protein concentrations were determined by the Bradford method (Bradford 1976) 
using BSA (Sigma-Aldrich, MO, USA) as a standard. Briefly, the PWM was 
resuspended in 600μl of protein extraction buffer and homogenized for 1 min, 
then centrifuged for 15 min at 14,000 x g at 4℃. For cells, the cultures were 
washed with cold PBS twice and resuspended in 600μl of protein extraction buffer. 
Cells were then scraped from the culture flask. The supernatant was collected by 
centrifugation at 14,000 x g at 4ºC for 15 min and stored at -20ºC for further use.   
The concentration of protein extracts was determined using a protein assay 
kit. Four different concentrations (0.06, 0.12, 0.24, and 0.48mg/ml) of BSA were 
prepared as protein standards. 10µl of each standard or sample and 200µl of 
protein assay dye reagent were added together to each well of a 96-well plate, and 
mixed thoroughly. The mixtures were incubated at room temperature for 10 min, 
and the absorbance at 595nm was measured using a microplate reader (GENios, 
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Tecan, Switzerland). The concentration of protein extract of the samples was 
determined according to the standard curve of BSA. 
Aliquots of protein extracts (20 µg each) were heated to 100ºC for 3 min in 
1x SDS gel-loading buffer to denature the proteins before they were separated by 
10% sodium dodecyl sulphate-polyacrylamide gel electrophoresis (SDS-PAGE). 
Next, the proteins were transferred from the gel to the 0.2µm polyvinylidene 
fluoride (PVDF) membranes using a semi-dry electrophoretic transfer cell 
(Bio-Rad, USA). Membranes were washed with TBST buffer and then blocked 
with 5% non-fat milk in TBST for 1h at room temperature. Subsequently, the 
membranes were incubated with appropriate primary antibodies overnight at 4ºC 
in an orbital shaker. The primary antibodies used are as follows (Table 3): rabbit 
anti- phospho-p38, p38, phospho-ERK1/2, ERK1/2, phospho-JNK, JNK, TNF-α, 
IL-1β, TNF-R1, IL-1R1, phospho-p65 NF-kappaB, phospho-IkappaB-α, IkappaB-a, 
p65 NF-kappaB, M-CSF, CSF-1R and goat anti-rat CCR2, MBP and mouse 
anti-β-actin. The following day, blots were incubated with secondary IgG antibody 
conjugated with horseradish peroxidase for 1h at room temperature. Equal amount 
of protein loading was confirmed by reprobing with total kinases or β-actin 
antibodies. Immunopositive bands were visualized by enhanced 
chemiluminescence, and quantified by scanning densitometer and Quantity One 
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2.7. Immunofluorescence labeling 
2.7.1. Materials 
All primary antibodies used in immunofluorescence labeling are listed in Table 3. 
CY3-conjugated goat anti-rabbit IgG (1:100; Sigma, Cat. No. AP307 F) lectin 
(1:100) 
Fluorescein isothiocyanate (FITC) conjugated goat anti-mouse (1:100 Chemicon 
International; Cat. No. AP130F) 
CY3-conjugated sheep anti-rabbit IgG (1:100, Sigma; Cat. No.c2306) 
FITC-conjugated goat-anti-rabbit secondary antibody (Chemicon, USA, AP307F) 
FITC-conjugated donkey-anti-goat secondary antibody (Chemicon, USA, 
AP106F) 
4’, 6-diamidino-2-phenylindole dihydrochloride (DAPI) (Sigma, USA, Cat. No. 
D1306) 
Fluorescent Mounting Medium (DakoCytomation, Denmark, Cat. No. S302380) 
PBS (10X) (Invitrogen, USA, Cat. No. 14200166)
0.1M PBS containing 0.1% Triton-X 100 (PBS-TX) 
4% paraformaldehyde (PF): 
    Paraformaldehyde (Sigma)      4g 
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2.7.2. Procedure for double immunoflourescence 
2.7.2.1 Double immunoflourescence in vivo 
Double immunofluorescence staining in the PWM from hypoxic rats along 
with their corresponding controls was carried out to confirm the cellular location 
of TNF-α, IL-1β, MCP-1, CCR2, M-CSF, TNF-R1, IL-1R1 and CSF-1R 
expression. Coronal frozen sections of the brain at the level of optic chiasma of 
40μm thickness were cut and rinsed in PBS. Endogenous peroxidase activity was 
blocked with 0.3% hydrogen peroxide in methanol for 30 min followed by rinsing 
with PBS. The sections were divided into five groups. The sections in the group 
Ⅰ were incubated with antibodies directed against TNF-α, IL-1β, MCP-1, CCR2, 
M-CSF (Table 3) overnight in a humidified chamber. This and all incubations to 
follow were at room temperature. On the following day, the sections were washed, 
and incubated with secondary antibody: CY3-conjugated goat anti-rabbit IgG 
(1:100; Sigma, Cat. No. AP307 F) for 1h. After this, the sections were washed and 
incubated with lectin (Lycopersicon esculentum; 1:100) for 1h. The sections in the 
group Ⅱ were incubated overnight with a cocktail mix of TNF-R1, IL-1R1 and 
monoclonal antibody against adenomatus polyposis coli (CC1) (Table 3). CC1 
antibody specifically stains the cell bodies of oligodendrocytes (Jantaratnotai et al. 
2003). Subsequent antibody detection was carried out with secondary antibodies: 
FITC-conjugated goat anti-mouse (1:100 Chemicon International; Cat. No. 
AP130F) for 1h. The sections were then washed and incubated with 
CY3-conjugated sheep anti-rabbit IgG (1:100, Sigma; Cat. No.c2306) for 1h. The 
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sections in the group Ⅲ were incubated overnight with a cocktail mix of CSF-1R, 
TNF-α, IL-1β and GFAP (Table 3). Subsequent antibody detection was carried out 
with secondary antibodies: FITC-conjugated goat anti-mouse (1:100 Chemicon 
International; Cat. No. AP130F) or with CY3-conjugated sheep anti-rabbit IgG 
(1:100, Sigma; Cat. No. 2306) for 1h. The sections in the group Ⅳ were incubated 
overnight with a cocktail mix of TNF-R1, IL-1R1 and NF-200 (Table 3) antibodies. 
NF-200 antibody specifically stains the axons. Subsequent antibody detection was 
carried out with secondary antibodies: FITC-conjugated goat anti-mouse (1:100 
Chemicon International; Cat. No. AP130F) or with CY3-conjugated sheep 
anti-rabbit IgG (1:100, Sigma; Cat. No.c 2306) for 1h. The sections in the group 
Ⅴ were incubated overnight with a cocktail mix of MBP and NF-200 (Table 3) 
antibodies. Subsequent antibody detection was carried out with secondary 
antibodies: FITC-conjugated donkey anti-goat (1:100 Santa Cruz Biotechnology; 
Cat. No.sc-2024) or with CY3-conjugated sheep anti-mouse IgG (1:100, Sigma; 
Cat. No.c2181) for 1h. Following rinsing in PBS, the sections were mounted with 
a fluorescent mounting medium (DAKO Cytomation, Denmark). Cellular 
colocalization was examined in a confocal microscope (LSM FV1000; Olympus 
Company Pte Ltd, Tokyo, Japan).  
2.7.2.2 Double immunoflourescence in vitro 
For cultured microglial cells, the cells were treated with 3% oxygen for either 
45 min (for c-Jun and phospho-c-Jun detection) or 4 h (for TNF-α, IL-1β, M-CSF 
or MCP detection). After the hypoxic treatment, the cells were fixed in 4% 
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paraformaldehyde for 30 min, blocked in 1% BSA for 30 min, and incubated with 
primary antibodies overnight at 4℃. Immunofluorescence labeling was carried out 
using primary antibodies directed against TNF-α, IL-1β, M-CSF or MCP, anti- 
phospho-c-Jun (Table 3). The cells were then incubated with CY3-conjugated 
goat-anti-rabbit secondary antibody (1:100, Sigma; Cat. No. AP307 F) for 1h. 
After this, the cells used for the detection of TNF-α, IL-1β, M-CSF and MCP 
expression were washed and incubated with lectin (1:100) for 1h.   
The cultured astrocytes were treated with M-CSF (25ng/ml) for 12h. After 
this, the cells were fixed in 4% paraformaldehyde for 30 min, blocked in 1% BSA 
for 30 min, and incubated with primary antibodies overnight at 4℃. 
Immunofluorescence labeling was carried out using primary antibodies directed 
against CSF-1R, TNF-α, IL-1β and GFAP (Table 3). The cells were then 
incubated with CY3-conjugated goat-anti-rabbit secondary antibody (1:100, Sigma; 
Cat. No. AP307 F) or with FITC-conjugated goat anti-mouse (1:100 Chemicon 
International; Cat. No. AP130F) for 1h.  
Finally, all the microglia or astrocytes were counterstained with DAPI and 
examined under a confocal microscope (LSM FV1000; Olympus Company Pte 
Ltd, Tokyo, Japan). 
Quantitative analysis of the number of phospho-c-Jun nuclear positive cells 
was carried out through counting 8 randomly selected microscopic fields at X40 
objective by a blinded observer. Each area contained about 40 cells in the control 
and microglial cultures treated with hypoxia. The cells with only blue nuclei were 
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counted as phospho-c-Jun negative, while those with blue nuclei overlapped with 
red were counted as phospho-c-Jun positive. The percentage of cells with positive 
expression for phosphor-c-Jun was calculated and averaged. Each experiment was 
done in triplicate. 
2.8. Electron microscopy 
The hypoxic rats and their corresponding controls were perfused with a 
mixed aldehyde fixative composed of 2% paraformaldehyde and 3% 
glutaraldehyde in 0.1M phosphate buffer, pH 7.2. After perfusion, the brain was 
removed and coronal slices (approximately 1mm thickness) were cut. Blocks of 
PWM were trimmed from these slices. Vibratome sections of 80-100 μm thickness 
were prepared from these blocks and rinsed overnight in 0.1M phosphate buffer. 
They were then postfixed for 2h in 1% osmium tetraoxide, dehydrated and 
embedded in Araldite mixture. Ultrathin sections were cut and viewed in a Philips 
CM 120 electron microscope.   
2.9. Detection of oligodendrocyte apoptosis by fluorescence terminal 
deoxynucleotidyl transferase (Tdt)-mediated dUTP nick end labelling 
(TUNEL) assay 
TUNEL assays were performed with an in situ cell death detection kit (Roche 
Diagnostics), according to the manufacturer’s instructions. Briefly, frozen sections 
were incubated at room temperature with CC1 antibody (Oncogene, mouse 
monoclonal IgG 1:20; Cat. No.OP80) overnight. Subsequent antibody detection 
was carried out with secondary antibody: CY3-conjugated sheep anti-mouse IgG 
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(1:100, Sigma; Cat. No. C2181) for 1h at 37°C in the dark. Then, the sections 
were washed and added 50ul TUNEL reaction mixture on sample. They were 
incubated in a humidified atmosphere for 60 min at 37℃ in the dark. 
Subsequently, the sections were washed and counterstained with DAPI. Finally, 
they were mounted with a fluorescent mounting medium and examined under a 
confocal microscope. The number of total and TUNEL positive oligodendrocytes 
in the PWM was calculated through counting 8 randomly selected microscopic 
fields in sections obtained from each rat (n=3) at X60 objective by a blinded 
observer. The percentage of TUNEL positive oligodendrocytes against the total 
number of oligodendrocytes was calculated and averaged. 
2.10. Cell counting and proliferation of AMC by lectin and 
5-bromo-2’-deoxyuridine (BrdU) labeling 
Lectin and BrdU labeling was used for cell enumeration and proliferation of 
AMC, respectively, in the PWM. BrdU (Sigma, MO, USA; Cat. No.B5002) was 
dissolved in 0.9% sodium chloride (10mg/ml) and injected intraperitoneally 
(100mg/kg) into neonatal rats 2h before sacrifice. The rats were anesthetized with 
0.6% sodium pentobarbital, and then perfused transcardially with 4% 
paraformaldehyde in PBS (pH 7.4). The brain was removed and post-fixed in 4% 
paraformaldehyde for 2h at 4℃, stored in 15% sucrose in PBS overnight. Coronal 
frozen sections of the brain at 30μm thickness at the level of optic chiasma were 
cut. A total of 8 sections at 30μm thickness each separated by a distance of 180 
μm were collected from each rat. Endogenous peroxidase activity was blocked 
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with 0.3% hydrogen peroxide in methanol for 30 min followed by rinsing with 
PBS. Subsequently, the sections were incubated in 2N HCl for 30 minutes at 37℃ 
to denature the DNA and then rinsed with PBS. They were incubated with mouse 
monoclonal antibody directed against BrdU (Sigma, MO, USA; Cat. No. B2531) 
overnight in a humidified chamber. On the following day, the sections were 
washed and incubated with secondary antibody: CY3-conjugated sheep anti-mouse 
IgG (1:100; Sigma, MO, USA; Cat. No. c-2181) for 1h. After this, the sections 
were washed and incubated with lectin (1:100) for 1h. Following rinsing in PBS, 
they were mounted with a fluorescent mounting medium (DAKO Cytomation, 
Denmark). Cell number and proliferation were determined in a confocal 
microscope (LSM FV1000; Olympus Company Pte Ltd, Tokyo, Japan). Lectin as 
well as BrdU labeled microglial cells in the PWM were identified and enumerated 
in the corresponding areas in different rats (n=3). A total of 8 randomly selected 
microscopic fields (each measuring an area of 4.5 mm2) at X40 objective from 
each section was scrutinized. Cells with a lectin (green) labeled fluorescent cell 
body overlapping with BrdU (red) labeled nucleus were counted as proliferating 
microglial cells, while those emitting only green fluorescence were 
nonproliferating microglial cells. The total number and percentage of proliferating 
microglial cells were calculated and averaged. 
2.11. Intracerebral stereotactic injection of MCP-1  
Wistar rats at 7 days of age were divided into sham-operated, vehicle (saline) 
injection and MCP-1 injection groups (n=8 for each respective group). Following 
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anesthetized with 6% sodium pentobarbital (60mg/kg), a scalp incision was made 
along the sagittal suture to access the skull, and a sharp beveled 10μl syringe 
needle was used to perforate the thin and soft skull. Four microlitres of MCP-1 
protein (Chemicon; Cat.No. GF 041) dissolved in saline (100 μg/ml) or saline 
alone was stereotaxically injected into the PWM at the following coordinates: 
1 mm posterior and 1 mm lateral to the bregma at a depth of 2 mm from the dural 
surface using a 10μl Hamiton syringe (Lehnardt et al. 2002). The tip of the needle 
was later confirmed in sections to reach the PWM of the above-mentioned rats. A 
hole was made on the skull of the sham-operated rats (n=8), but microinjections 
were not conducted. Rats were killed at 8 hours after injection.  
2.12. Cell counting of AMC following MCP-1 injection labeled with lectin or 
OX-42. 
The rats receiving MCP-1 intracerebral injection were anesthetized with 
0.6% sodium pentobarbital, and then perfused transcardially with 4% 
paraformaldehyde in PBS (pH 7.4). The brain was removed and post-fixed in 4% 
paraformaldehyde for 2h at 4℃, stored in 15% sucrose in PBS overnight. Coronal 
frozen sections of the brain at 30μm thickness at the level of optic chiasma were 
cut. Lectin or OX-42 labeled AMC along and around the needle track in the PWM 
were identified and counted. Four sections (30μm thick) each separated by a 90μm 
interval derived from MCP-1 injected and sham-operated rats were examined for 
labeled cells. Endogenous peroxidase activity was blocked with 0.3% hydrogen 
peroxide in methanol for 30 min followed by rinsing with PBS. The tissue 
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sections labeled with lectin were then incubated with lectin (1:100) for 1h at room 
temperature. Following rinsing in PBS, they were mounted with a fluorescent 
mounting medium (DAKO Cytomation, Denmark).  
However, lectin labeled both microglia and blood vessels. Therefore, OX-42, 
another microglial marker which does not recognize blood vessels, was used to 
stain microglial cells. The tissue sections labeled with OX-42 were then incubated 
with mouse monoclonal antibody directed against OX-42 (1:100; 
Harlan-Sera-Laboratory, Loughborough, UK; Cat. No.O-MAS 370b) overnight in 
a humidified chamber. On the following day, the sections were washed and 
incubated with secondary antibody: FITC-conjugated rabbit anti-mouse IgG 
(1:100; Chemicon International; Cat. No.F9137) for 1h. After this, they were 
washed and mounted with a fluorescent mounting medium (DAKO Cytomation, 
Denmark). 
Cell counting was carried out under a confocal microscope (LSM FV1000; 
Olympus Company Pte Ltd, Tokyo, Japan). Lectin or OX-42 positive microglial 
cells around the needle track in the PWM and in the corresponding area on the 
contralateral side was enumerated in 4 randomly selected microscopic fields (each 
measuring 4.5 mm2) from 8 rats, respectively, at X 40 objective.  
2.13. ELISA 
2.13.1. Materials 
MCP-1 ELISA kit (Pierce, USA, Cat. No. ERMCP1) 
ELISA plate reader (Molecular Devices, USA) 
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2.13.2. Analysis of MCP-1 by ELISA 
For the PWM, tissue proteins were extracted using protein extraction kit 
according to the manufacturer's protocol. Protein concentrations were determined 
by the Bradford method (Bradford 1976) using BSA (Sigma-Aldrich, MO, USA) 
as a standard. For microglial cultures, cells were subjected to hypoxia exposure 
for 1, 2, 4 and 6h or hypoxia plus BAY 11-7082 (10mM; Calbiochem, San Diego, 
CA, USA) for 4 h, and the culture medium from each experiment was collected. 
MCP-1 concentration in the PWM or released from microglial cells in the culture 
medium was measured using the rat MCP-1 ELISA kit (Pierce, Rockford, IL, 
USA; Cat. No. ERMCP1) according to the manufacturer’s protocol. Briefly, 
samples including standards of known MCP-1 content were incubated in 96-well 
plates coated with MCP-1 antiserum for 2 h. The samples were treated in 
subsequent steps with enzyme working reagent for 30 min and 
tetramethylbenzidine One-Step substrate reagent for 30 min in the dark and the 
reaction plates were read within 30 min in an ELISA plate reader (Molecular 
Devices, Eugene, OR, USA) at 450 nm. 
2.14. Chemotaxis  
2.14.1. Materials 
48-well Boyden. microchamber (Neuro Probe, USA, Cat. No. AP48) 
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2.14.2. Procedure  
In vitro migration of microglia in response to microglia conditioned medium 
was assessed using polyvinylcarbonate-free membranes with 10 μm pore size in a 
modified 48-well microchemotaxis Boyden chamber (Neuroprobe, Cabin John, 
MD, USA) as described previously (Cross and Woodroofe 1999b;Zhou et al. 
2007a). The membrane was coated with 20 μg/mL of fibronectin (BD Bioscience, 
Bedford, MA, USA; Cat. No. 354008) for 24 h. Microglial cells were plated at 
2.5 × 105 per well on a 24 multi-well culture dish for 24h and incubated with 3% 
oxygen for 4 h. To examine the chemotactic migration of microglia, 28 μL of 
DMEM or conditioned medium collected from the control and hypoxia treated 
microglial cultures was added to the lower chambers. In addition, rabbit 
anti-MCP-1 antiserum (10 μg/mL; Cytolab, Rehovot, Israel; Cat. No. 500-P76) or 
another unrelated antiserum raised in rabbit (10 μg/mL; anti-iNOS; Chemicon; 
Cat. No. AB5382) as the control was added in the hypoxia-treated microglia 
conditioned medium in the lower chambers to test the neutralization effects of 
anti-MCP-1.  
    Microglial cells (1 × 106/mL) in 50 μL of serum free migration medium, 
DMEM and 0.5% BSA were incubated in the upper chambers for 6 h at 37°C in a 
humidified atmosphere of 5% CO2 and 95% air. At the end of experiment, the 
upper surfaces of membranes were scraped free of cells and debris, fixed in 4% 
paraformaldehyde and stained using crystal violet. Cells that had migrated through 
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pores and adhered to the lower surfaces of the membranes were counted under the 
light microscope and photographed. 
2.15 Statistical Analysis 
The data of experiments were presented as mean ±standard deviation (SD). 








Where, x = individual observation, and n = number of observations 
Statistical significance was evaluated by the Student’s t-test. Results were 
considered as significant at p<0.05. 
 66
Results 























3.1 Real time RT-PCR analysis of TNF-α, IL-1β, TNF-R1 and IL-1R1, M-CSF, 
CSF-1R, MCP-1 and CCR2 mRNA expression in the PWM 
The location of PWM is shown in Fig.1. TNF-α mRNA expression was 
significantly increased in the PWM at 3 and 24 h , 3 and 7d after the hypoxic 
exposure in comparison with the corresponding controls (p < 0.05) (Fig 2A). 
Increase in IL-1β mRNA expression paralleled that of TNF-α mRNA after the 
hypoxic exposure at 3 and 24 h, 3 and 7d as compared with the corresponding 
controls (p < 0.05) (Fig 2B). There was no significant change in mRNA 
expressions of TNF-α and IL-1β at 14d after hypoxia when compared with the 
corresponding control rats (Fig 2A, B). TNF-R1 mRNA expression remained 
relatively unchanged at 3 and 24h (Fig 2C), but was markedly increased at 3d and 
was sustained till 14d in hypoxic rats when compared with the controls (p < 0.05) 
(Fig 2C). Increased IL-1R1 mRNA expression was first observed at 24h peaking at 
3d and was maintained at a high level till 14d after the hypoxic exposure in 
comparison with the controls (p < 0.05) (Fig 2D). There was no significant 
change in IL-1R1 mRNA expression at 3h after the hypoxic exposure when 
compared with the corresponding control rats (Fig 2D). M-CSF mRNA expression 
was significantly increased in the PWM at 3 and 24 h, 3 and 7d after the hypoxic 
exposure in comparison with the corresponding controls (p < 0.05) (Fig 3A). 
There was no significant change in mRNA expression of M-CSF at 14d after 
hypoxia when compared with the corresponding control rats (Fig 3A). CSF-1R 
mRNA expression remained relatively unchanged at 3h (Fig 3B), but was 
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markedly increased at 24h and was sustained till 14d in hypoxic rats when 
compared with the controls (p < 0.05) (Fig 3B). MCP-1 and CCR2 mRNA 
expression levels were significantly increased in the PWM at 3, 24 h, 3 and 7d 
after the hypoxic exposure in comparison with the corresponding controls (Fig 3C, 
D)(p < 0.05). There was no significant difference between the mRNA expression 
of MCP-1 and CCR2 at 14d when compared with the corresponding control rats 
(Fig 3A). 
3.2 Western blotting or ELISA analysis of TNF-α, IL-1β, TNF-R1 and IL-1R1, 
M-CSF, CSF-1R, MCP-1 and CCR2 protein expression in the PWM  
The immunoreactive bands of TNF-α and IL-1β protein levels that appeared 
at approximately 30kDa and 17 kDa, respectively (Fig 4A), increased significantly 
(p < 0.05) in optical density at 3 , 24 h, 3 ,7 and 14 d after hypoxic exposure as 
compared with the controls (Fig 4B and Fig 4C). The immunoreactive band of 
TNF-R1 protein levels appeared at approximately 55kDa (Fig 4A). The optical 
density was increased significantly (p < 0.05) at 7 and 14 d after hypoxic 
exposure as compared with the controls (Fig 4D). However, there was no 
expression of TNF-R1 protein at 3, 24h and 3d in the both hypoxic and control rats. 
The immunoreactive band of IL-1R1 protein levels appeared at approximately 
80kDa (Fig 4A). It was augmented significantly (p < 0.05) at 24h, 3, 7 and 14 d 
after hypoxic exposure when compared with the controls (Fig 4E). There was no 
significant change in protein expression of IL-1R1 at 3h after the hypoxic exposure 
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when compared with the corresponding control rats. 
The immunoreactive band of M-CSF protein levels that appeared at 
approximately 18.5kDa (Fig 5A), increased significantly (p < 0.05) in optical 
density at 3 , 24 h, 3, 7 and 14d after hypoxic exposure as compared with the 
controls (Fig 5A, B). The immunoreactive band of CSF-1R protein level, appeared 
at approximately 170kDa (Fig 5A), was augmented significantly (p < 0.05) at 24h, 
3, 7 and 14 d after hypoxic exposure when compared with the controls (Fig 5A, C). 
There was no significant difference between the protein expression of CSF-1R at 
3h after the hypoxic exposure when compared with the corresponding control rats. 
ELISA analysis showed that MCP-1 protein release was significantly increased at 
3, 24h, 3 and 7d after the hypoxic exposure as compared with the corresponding 
controls (Fig 5F) (p < 0.05). There was no significant change in the protein 
release of MCP-1 at 14d after the hypoxic exposure when compared with the 
corresponding control rats. The immunoreactive bands of CCR2 protein levels that 
appeared at approximately 47kDa (Fig 5D), increased significantly (p < 0.05) in 
optical density at 3 , 24 h, 3 and 7 d after hypoxic exposure as compared with the 
controls (Fig 5D, E).                                 
3.3 Cellular localization of TNF-α, IL-1β, TNF-R1 and IL-1R1, M-CSF, CSF-1R, 
MCP-1 and CCR2 protein expression in the PWM by double labeling 
In the PWM of the control rats sacrificed at 24h, TNF-α as well as IL-1β 
expression was specifically detected in sporadic cells, confirmed to be the AMC 
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by double labelling with lectin staining (Fig 6 A-C, G-I). At 24 h following 
hypoxic exposure, immunoreactivity for TNF-α and IL-1β was detected and 
enhanced in large numbers of AMC (Fig 6 D-F, J-L) when compared with the 
controls (Fig 6 A-C, G-I). However, there was no noticeable change in TNF-α and 
IL-1β expression in the astrocytes at 24h after the hypoxic exposure (Fig 7 D-F; 
Fig 8 D-F) when compared with the corresponding control rats (Fig 7 A-C; Fig 7 
A-C). In the PWM of the control rats sacrificed at 7 and 14d, TNF-α and IL-1β 
immuno expression was detected in occasional cells, confirmed to be the 
astrocytes by double labeling with GFAP (Fig 7 A-C, G-I, M-O; Fig 8 A-C, G-I, 
M-O). At 7 and 14d following hypoxic exposure, very intense TNF-α and IL-1β 
immunoreactivity was detected in large numbers of astrocytes which appeared 
hypertrophic (Fig 7 J-L, P-R; Fig 8 J-L, P-R) when compared with the controls 
(Fig 7 G-I, M-O; Fig 8 G-I, M-O).  
Expression of TNF-R1 and IL-1R1 was localized in the soma of occasional 
oligodendrocytes as confirmed by double immunofluorescence showing 
colocalization of CC1 (Fig 9 A-L). At 7d following hypoxic exposure, 
immunoreactivity for TNF-R1 and IL-1R1 was markedly enhanced in the soma of 
oligodendrocytes (Fig 9 D-F, J-L) as compared with the control (Fig 9 A-C, G-I). 
In the control rats at 14 days, moderate TNF-R1 and IL-1R1 immunofluorescence 
was localized in some small cells as well as the axons as confirmed by double 
immunofluorescence showing colocalization of NF-200 (Fig 10 A-C, G-I). 
Following hypoxic exposure, TNF-R1 and IL-1R1 immunoreactivity was markedly 
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enhanced being more conspicuous along the closely packed axons (Fig 10 D-F, 
J-L).  
In the PWM of the control rats, moderate M-CSF expression was 
specifically detected in sporadic cells, confirmed to be the AMC by double 
labelling with lectin staining (Fig 11 A-C, G-I). At 3 and 7d following hypoxic 
exposure, M-CSF immunoreactivity was enhanced in AMC (Fig 11 D-F, J-L) 
when compared with the controls (Fig 11 A-C, G-I). CSF-1R expression was 
barely detected in the astrocytes in the control rats (Fig 12 A-C, G-I) as confirmed 
by its co-localization with GFAP. At 7 and 14d following hypoxic exposure, 
CSF-1R immunoreactivity was markedly enhanced in the astrocytes (Fig 12 D-F, 
J-L).  
In the control rats, MCP-1 and CCR2 expression was specifically detected in 
the AMC as confirmed by double labeling with lectin (Fig 13 A-L, Fig 14 A-L, 
Fig 15 A-L). At 3, 24 h, 3 and 7d following hypoxic exposure, intense MCP-1 
immunoreactivity was induced in large numbers of AMC (Fig 13 D-F, J-L; Fig 14 
D-F, J-L) when compared with the controls (Fig 13 A-C, G-I; Fig 14 A-C, G-I). At 
3 h and 3d following hypoxic exposure, immunoreactivity for CCR2 was detected 
and enhanced in large numbers of AMC (Fig 15 D-F, J-L) when compared with 
the controls (Fig 15 A-C, G-I).   
3.4 MBP and NF-200 protein expression in the PWM  
MBP and NF-200 protein expression was significantly decreased in the 
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PWM at 14 days after the hypoxic exposure in comparison with the corresponding 
controls (Fig 16 A-H). The immunoreactive bands of MBP protein levels (Fig 16 
A), decreased significantly (p < 0.05) in optical density at 14 d after hypoxic 
exposure as compared with the controls (Fig 16 A, B). However, MBP protein 
expression was undetected at 3 and 24h, 3 and 7 days in both the hypoxic and 
control rats. Confocal images showed that the MBP positive processes and 
NF-200 positive axons were extensively disrupted following the hypoxic exposure 
(Fig 16 F, G) as compared with the control (Fig 16 C, D).   
3.5 Apoptosis of oligodendrocytes in the PWM  
     Immunoreactive CC1 labeled oligodendrocytes characterized by an oval cell 
body were identified in the PWM in the control rats (Fig 17A-C). There was less 
evidence of cells marked by TUNEL labeling (Figure 17 B). Following hypoxia 
exposure, however, CC1 immunoreactive cells showing TUNEL labeled nucleus 
were increased significantly (Fig 17 D-F). The percentage of TUNEL positive 
oligodendrocytes at 7d following hypoxic exposure was significantly higher than 
that in the corresponding controls (Fig 17 G). Another salient feature in the 
hypoxic rats was that the number of CC1 positive immunoreactive 
oligodendrocytes/mm2 was decreased significantly (Fig 17 D-F, H).  
3.6 Ultrastructural observations  
     Apoptotic and necrotic cells were common features in the PWM of hypoxic 
rats at 24h, 3 and 7d (Fig 18 A-D). Necrotic cells were characterized by swollen 
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and vacuolated cytoplasm, disrupted organelles, and disintegrated membranes in 
the PWM at 24h (Fig. 18 A) and 7d (Fig. 18 C) after the hypoxic exposure. 
Apoptotic cells which occurred in the PWM at 24h (Fig. 18 B) and 7d (Fig. 18 C) 
after the hypoxic exposure exhibited nuclear shrinkage and chromatin 
condensation. Both degenerating cell types appeared to be phagocytosed by the 
AMC (Fig 18 E-F). Both apoptotic and necrotic cells were rarely encountered in 
the PWM of the control rats. The most striking structural alteration after the 
hypoxic exposure was swelling of a variable number of axons which appeared 
club shaped in sections throughout the period of study (Fig 19 A, C). Many of the 
dilated axons were vesiculated (Fig 19 A, C). Hypoxia also affected the 
myelinated axons which appeared distorted (Fig 19 B, D). In some sectional 
profiles, myelin-like figures appeared to be internalized in the axoplasm (Fig 19 B, 
D). 
3.7 Increase in cell numbers of AMC in the PWM in hypoxic neonatal rats  
The number of AMC was significantly increased in the PWM at 3, 24h, 3 and 
7d after the hypoxic exposure in comparison with the corresponding controls (Fig 
20 A-L; Fig 20 M; Fig 21 A-L; Fig 21 M)(p < 0.01). Very few AMC were double 
labeled with lectin and BrdU at 3, 24h and 3d after the hypoxic exposure and the 
matching controls (Fig 20 A-L; Fig 21 A-F) (p < 0.01). There was no significant 
difference in the proliferation rate of microglia at these time points between the 
hypoxic rats and the corresponding controls (Fig 20 N; Fig 21 N). The rate was 
determined by the ratio between double labeled cells against microglia labeled by 
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lectin only. More lectin labeled AMC were BrdU immunoreactive at 7d after the 
hypoxic exposure in comparison with the control (Fig 21 G-L). The proliferation 
rate of AMC in the hypoxic rats was significantly increased as compared with the 
controls (Fig 21 N) (p < 0.01). 
3.8 MCP-1 induced microglial migration in vivo 
     Lectin or OX-42 labeling showed a large accumulation of microglial cells 
around the needle track in the PWM of 7d old rats receiving MCP-1 injection (Fig 
22 G-H; Fig 23 G-H) when compared with those given saline injection or 
sham-operated rats (Fig 22 A-B, D-E, J; Fig 23 A-B, D-E, J). More microglial 
cells were observed in the PWM ipsilateral to MCP-1 injection when compared to 
the corresponding areas on the contralateral side (Fig 22 G-J; Fig 23 G-J). In rats 
given saline injection, the number of microglial cells along the needle track was 
not significantly different from the corresponding areas contralaterally (Fig 22 D-F, 
J; Fig 23 D-F, J). 
3.9 In vitro mRNA and protein expression of TNF-α, IL-1β, M-CSF and MCP-1 
in activated microglia under hypoxic conditions 
An upregulation of TNF-α mRNA expression was observed at different time 
points after hypoxia peaking at 2h (p < 0.05) when compared with the matching 
controls (Fig 24 A). The IL-1β mRNA expression was likewise increased after the 
hypoxic exposure peaking at 1 h as compared with the controls (p < 0.05) (Fig 24 
B). M-CSF mRNA (Fig 24 C) expression was significantly upregulated peaking at 
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4h (p < 0.05) after the hypoxic exposure when compared with the controls. 
MCP-1 mRNA expression was significantly increased at different time points after 
hypoxia peaking at 4h (p < 0.05) when compared with the matching controls 
(Fig 24 D). 
Upregulation of TNF-α protein peaking at 4h (p < 0.05) after the hypoxic 
exposure was observed when compared with the controls (Fig 25 A, B). The IL-1β 
protein quantity also increased significantly after the hypoxic exposure peaking at 
4h as compared with the controls (p < 0.05) (Fig 25 A, C). Double 
immunofluorescence labeling showed that the lectin labeling in microglial cells 
was completely co-localized with TNF-α and IL-1β expression (Fig 26 A-L). At 
4h after hypoxia, the expression of TNF-α and IL-1β in microglial cells was 
increased significantly (Fig 26  D-F, J-L) in comparision with the control cells (Fig 
26 A-C, G-I).  
M-CSF protein (Fig 25 A, D) expression was significantly upregulated 
peaking at 4h (p < 0.05) after the hypoxic exposure when compared with the 
controls. Double immunofluorescence labeling showed that the lectin labeling in 
microglial cells was completely co-localized with M-CSF expression (Fig 27 A-F). 
At 4h after hypoxia, M-CSF immunofluorescence in microglial cells was 
markedly increased (Fig 27 D-F) in comparison with the control cells (Fig 27 
A-C).  
MCP-1 protein release as revealed by ELISA at 1, 2, 4 and 6h after the 
hypoxic exposure peaking at 4h (p < 0.05) was augmented when compared with 
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the controls (Fig 25 E). Double immunofluorescence labeling showed that lectin 
labeling in microglial cells was completely co-localized with MCP-1 expression 
(Fig 27 G-L). At 4h after hypoxia, MCP-1 immunoexpression in AMC was 
markedly increased (Fig 27 G-I) in comparision with those in the control rats (Fig 
32 J-L).  
3.10 Hypoxia induced the TNF-α and IL-β production via activation of MAP 
kinase pathway in activated microglia  
MAP kinase signaling transduction pathway plays a significant role in 
inducing the expression of inflammatory genes in many immune cell types. We, 
therefore, examined whether hypoxia induced the activation of MAP kinases in 
primary microglial cultures. Western blot analysis showed that the hypoxia 
treatment induced rapid and time-dependent phosphorylation of JNK (Fig 28 A, H) 
and p38 (Fig 28 B, I) in microglial cells. The phosphorylated JNK and p38 levels 
increased at 30 min and gradually declined to basal levels at 4h. In addition, 
hypoxia treatment induced phosphorylation of ERK1/2 in microglial cells (Fig 28 
C, J). The phosphorylated ERK level was increased to peak at 30min of incubation. 
Unlike JNK and p38, however, ERK1/2 level was only moderately decreased at 1, 
2 and 4h after hypoxia. Since JNK mediates N-terminal phosphorylation of c-Jun, 
effect of hypoxia on the c-Jun phosphorylation was examined. Phospho-c-Jun 
immunoreactivity was detected in a few microglial cells in the control.  It was 
markedly induced in a majority of microglial cells in cultures treated with 3% 
oxygen (Fig 29 D-F) when compared with the controls (Fig 29 A-C). The 
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percentage of phospho-c-JUN positive microglial cells treated with 3% oxygen 
was significantly higher than the controls (Fig 29 G) (p < 0.01). Majority of the 
microglial cells exhibited total c-Jun immunoreactivity, and the treatment of 
hypoxia did not affect the total c-Jun immunoreactivity in microglial cells.      
It was hypothesized that hypoxia induced TNF-α and IL-1β production in 
activated microglial cells by altering the MAP kinase pathways. In order to 
address this, TNF-α and IL-1β productions were measured by Western blotting in 
hypoxia-induced microglial cells exposed to pharmacological agents, SP600125 
and SB203580, which are selective inhibitors of JNK and p38, respectively. 
Incubation of microglial cells with SP600125 or SB203580, 30min prior to 
hypoxia treatment for 4h decreased the hypoxia-induced TNF-α and IL-1β 
expression (Fig 28 D, K; F, M; E, L; G, N).  
3.11 Hypoxia induced MCP-1 production via activation of NF-kappaB signaling 
pathway in microglia  
    Western blot analysis showed that hypoxia induced rapid and time-dependent 
increase in NF-kappaB (Fig 30 B, F) (*p< 0.05) and phosphorylation of 
NF-kappaB (Fig 30 A, E) (*p< 0.05). The NF-kappaB and phosphorylated 
NF-kappaB levels increased at 15 min peaking at 1h. In addition, hypoxia 
treatment induced rapid degradation of phosphorylated IkappaB whose level 
declined gradually at 15, 30 min, 1 and 2h after hypoxic exposure (Fig 30 C, 
G)(*p< 0.05). There was no significant difference in the expression of IkappaB at 
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different time points after hypoxic exposure when compared with the controls (Fig 
30 D, H) (**p> 0.05). 
It was hypothesized from the above results that hypoxia induced MCP-1 
production in activated microglial cells was via the NF-kappaB signaling 
pathways. To ascertain this, MCP-1 production was measured by ELISA in 
hypoxia-induced microglial cells culture medium exposed to the pharmacological 
agent, BAY, a selective inhibitor of NF-kappaB. Incubation of microglial cells 
with BAY, 30min prior to hypoxia treatment for 4h, decreased the 
hypoxia-induced MCP-1 release (Fig 30 I) (*p < 0.05).  
3.12 TNF-α, IL-1β and CSF-1R mRNA and protein expression in activated 
astrocytes after M-CSF treatment  
An upregulated TNF-α mRNA expression was observed at 3, 6 and 12h after 
M-CSF treatment peaking at 3h (p < 0.05) when compared with the matching 
controls (Fig 31 A). IL-1β mRNA expression was concomitantly increased 
peaking at 3 h as compared with the controls (p < 0.05) (Fig 31 B). There was no 
significant change in the expression levels of TNF-α and IL-1β mRNA at 24h 
when compared with the corresponding controls (Fig 31 A, B). CSF-1R mRNA 
expression was significantly increased at different time points following treatment 
with M-CSF peaking at 12h (p < 0.05) when compared with the matching controls 
(Fig 31 C). Upregulation of TNF-α protein level peaking at 3h (p < 0.05) after the 
hypoxic exposure was observed when compared with the controls (Fig 31 D, E). 
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IL-1β protein level also increased significantly after the hypoxic exposure peaking 
at 3h as compared with the controls (p < 0.05) (Fig 31 D, F). CSF-1R protein 
levels were increased significantly (p < 0.05) at 3, 6, 12 and 24h with M-CSF 
treatment when compared with the control (Fig 31 D, G). Double 
immunofluorescence labeling showed that GFAP labeling in the astrocytes was 
completely co-localized with TNF-α, IL-1β and CSF-1R expression (Fig 32 A-R). 
At 12h, TNF-α, IL-1β and CSF-1R immunofluorescence in the astrocytes was 
greatly intensified (Fig 32 D-F, J-L, P-R) in comparison with the control cells (Fig 
32 A-C, G-I, M-O).  
3.13 Increased TNF-α and IL-β production in activated astrocytes after M-CSF 
treatment was via activation of MAP kinase pathway  
Whether MAP kinases were activated in primary astrocytes cultures after 
M-CSF treatment was further examined. Western blot analysis showed that the 
treatment with M-CSF induced rapid and time-dependent phosphorylation of JNK 
(Fig 33 A, H) in the astrocytes. The phosphorylated JNK levels increased at 15 
min and gradually declined to basal levels at 2h. However, the time-dependent 
phosphorylation of p38 was not observed in the astrocytes after M-CSF treatment 
(Fig 33 B, I). In addition, treatment with M-CSF induced phosphorylation of 
ERK1/2 in the astrocytes (Fig 33 C, J). The phosphorylated ERK level peaked at 
15min after M-CSF treatment, but unlike JNK, ERK1/2 level was only moderately 
decreased at 1 and 2h.   
 80
Results 
It was hypothesized that TNF-α and IL-1β production induced after M-CSF 
treatment in activated astrocytes was mediated by the MAP kinase pathways. To 
ascertain this, TNF-α and IL-1β production was measured by Western blotting in 
M-CSF-treated astrocytes exposed to pharmacological agents, SP600125 and 
SB203580, which are selective inhibitors of JNK and p38, respectively. 
Incubation of astrocytes with SP600125, 30 min prior to treatment with M-CSF 
for 3h decreased the M-CSF treatment-induced TNF-α and IL-1β expression (Fig 
33 D, K; Fig 33 E, L). However, incubation of astrocytes with SB203580, 30 min 
prior to treatment with M-CSF for 3h did not alter the M-CSF treatment-induced 
TNF-α and IL-1β expression (Fig 33 F, M; Fig 33 G, N). This indicates that TNF-α 
and IL-β production induced in activated astrocytes after M-CSF treatment was 
via activation of JNK-MAP kinase pathway.  
3.14 Migration of microglia to medium derived from microglial culture 
subjected to hypoxia 
The chemotactic effects of the conditioned-medium derived from the control 
(untreated) microglial culture, microglia culture treated with hypoxia with or 
without anti-MCP-1 antiserum on the migration of microglial cells were next 
investigated. Only a few crystal violet-stained microglia transmigrated through the 
membrane of insert in a transwell chamber in the DMEM medium (Fig.34A, B). 
The conditioned-medium derived from hypoxia-treated microglial cultures 
attracted significantly more migratory microglial cells than the control medium 
(Fig.34A, B). The number of hypoxia-induced transmigrated microglia, however, 
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was markedly reduced in hypoxia + anti-MCP-1 antiserum medium (Fig.34A, B). 
When the hypoxia-treated medium was treated with an unrelated antiserum from 
the same species of anti-MCP-1 as the control, the migration of microglia was not 















PWMD refers to damage of the immature deep cerebral white matter 
peripheral to the lateral ventricles, occuring in the perinatal period (Folkerth et al. 
2004). Inflammatory response induced by various stimuli has been recognized as a 
common feature in the pathogenesis of PWMD (Chew et al. 2006). Production of 
inflammatory mediators such as cytokines, chemokines and free radicals has been 
thought to be associated with PWMD (Folkerth 2006; Chew et al. 2006). 
Activated microglia and astrocytes release inflammatory mediators under 
pathological conditions. Studies have shown that besides microglial cells in the 
brain, astrocytes have the ability to produce inflammatory mediators (such as 
TNF-α) and free radicals (Sawada et al. 1995). A large number of cytokines and 
chemokines produced by activated microglial cells or astrocytes execute noxious 
effects on developing oligodendrocytes progenitors and axons through their 
respective receptors.  
4.1 Microglia are activated and induce a robust and persistent inflammatory 
response in the PWM in hypoxic neonatal rats 
It has been well documented that hypoxia is an important stimulus that 
initiates an inflammatory response with enormous production of inflammatory 
chemokines and cytokines (Carloni et al. 2006; Guo and Bhat 2006; Saed et al. 
2005). Microglia activation with overproduction of inflammatory cytokines, free 
radicals, NO and excess glutamate release is a hallmark feature in the 
development of hypoxic brain injury. It is well established that microglial cells are 
activated and involved in hypoxia-induced damage in the developing brain (Kaur 
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et al., 2008; Li et al., 2008b; Li et al., 2009). Activated microglia can change their 
cellular morphology, proliferate, potentiate phagocytosis, actively migrate to the 
site of injury, and produce various factors including growth factors, NO, cytokines, 
and chemokines and thereby cause an inflammatory response (Farber and 
Kettenmann, 2006; Dheen et al., 2007; Hanisch and Kettenmann, 2007). 
Concomitantly, activated microglia produce other molecules such as syndecan-2 
and exhibit enhanced expression of ion channels such as Kv1.2 and Kv1.1 (Li et al. 
2008a; Kaur et al. 2009; Wu et al. 2009). All these would further promote the 
release of inflammatory cytokines, chemokines and ROS by microglia and greatly 
amplify the brain injury in the hypoxic neonatal rats (Li et al. 2008a; Kaur et al. 
2009; Wu et al. 2009). 
In addition to inflammatory cytokines and chemokines, recent studies have also 
demonstrated that the expression of N-methyl-D-aspartic acid (NMDA) receptors 
is upregulated on the microglia in hypoxic conditions (Kaur et al 2006). 
Immunostimulated microglia are reported to aggravate the NMDA 
receptor-induced excitotoxicity by expression of iNOS (Kaur et al 2006). 
Microglial cells also express -amino-3-hydroxy-5-methyl-4-isoxazole propionic 
acid -kainate (AMPA-KA) receptors (Noda et al. 2000; Sivakumar V et al 2009), 
the activation of which increases the generation of TNF-α which induces 
oligodendrocyte death (Selmaj et al. 1988; Louis et al. 1993), destruction of 
myelin sheath and the dysfunction of axons (Merrill et al. 1996). 
The present study has shown an up-regulation of TNF-α, IL-1β, MCP-1 and 
 85
Discussion 
M-CSF mRNA expression in the PWM of neonatal rats following a hypoxic 
exposure up to 7d suggesting that an inflammatory response occurs in the PWM 
of neonatal rats after hypoxic insult. ELISA analysis showed that MCP-1 protein 
release was significantly increased up to 7d after the hypoxic exposure. Western 
blotting results have further demonstrated that protein expression of TNF-α, IL-1β 
and M-CSF in the PWM was increased throughout the period of study i.e. up to 
14d in hypoxic rats. However, there was no significant difference between the 
mRNA expressions of TNF-α, IL-1β and M-CSF at 14d in hypoxic rats when 
compared with the corresponding control rats. A possible explanation is that 
TNF-α, IL-1β and M-CSF protein synthesis occurs later than their mRNA 
expression. Double immunofluorescence staining has shown that expression of 
TNF-α, IL-1β, MCP-1 and M-CSF was detected in AMC as verified by their 
co-localization with lectin, a cellular marker for microglial cells. AMC expressed 
TNF-α, IL-1β, MCP-1 and M-CSF up to 7 days in hypoxic rats. This suggests that 
in the evolution of inflammation in the developing brain, the AMC would be the 
main cellular source for proinflammatory chemokine and cytokine production up 
to 7 days after hypoxic insult. Concomitantly, the present study has also found an 
up-regulated TNF-α and IL-1β expression in the astrocytes in the same brain area 
at 7 and 14d following a hypoxic exposure. It has been reported that under 
inflammatory conditions microglia may be responsible for the early phase of 
inflammatory response and astrocytes may contribute to inflammatory response at 
later stages (Sawada et al. 1995). Taken together, this suggests that in the 
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progression of inflammation in the white matter in the developing brain, while the 
AMC play major role at an early stage or acute phase in production of TNF-α, 
IL-1β, MCP-1 and M-CSF, the astrocytes would be the main cellular source for 
proinflammatory cytokine production at a late stage i.e 7-14d after hypoxic insult.  
4.2 In vitro Hypoxia induce microglia release TNF-α, IL-1β, MCP-1 and 
M-CSF  
Hypoxia is a known activator of microglial cells. The present in vitro study 
has found that the mRNA and protein expression of inflammatory chemokines and 
cytokines such as TNF-α, IL-1β, MCP-1 and M-CSF in cultured microglia was 
increased significantly after hypoxia exposure for 4h. This suggests that hypoxia 
can elicit isolated microglia to produce inflammatory cytokines and chemokines 
directly. 
4.2.1 MCP-1 is released by activated AMC via NF-kappaB signaling pathway 
under hypoxic conditions 
     It has been reported recently that NF-kappaB proteins function as dimeric 
transcription factors that control genes regulating a broad range of biological 
processes including inflammation, stress responses, innate and adaptive immunity 
(Li and Verma 2002;Pomerantz and Baltimore 2002). Under physiological 
conditions, NF-kappaB proteins are bound and inhibited by IkappaB proteins 
(Karin et al. 2002). Under pathological conditions, IKK complexes (IKKβ, IKKα 
and NEMO) are activated, which phosphorylate IkappaB proteins. 
Phosphorylation of IkappaB leads to its rapid ubiquitination and proteasomal 
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degradation, freeing NF-kappaB (Ghosh and Karin 2002). Active NF-kappaB 
proteins are subsequently phosphorylated, then translocated to the nucleus where 
they induce target gene expression (Pahl 1999). The present results have 
demonstrated that the NF-kappaB and phosphorylated NF-kappaB levels were 
markedly increased at 1h but gradually declined to basal levels at 2h in hypoxic 
microglial cells. The phosphorylated IkappaB was gradually degraded at each time 
point after hypoxic exposure in the microglial cells. Incubation of microglial cells 
with BAY 11-7082, a selective inhibitor of NF-kappaB (Ohkita et al. 2002), 30 
minutes prior to hypoxia treatment for 4h decreased the hypoxia-induced MCP-1 
release. On the basis of this, we speculate that hypoxia induced release of MCP-1 
from microglial cells in the PWM occurs through NF-kappaB signaling pathway.  
4.2.2 TNF-α and IL-1β are produced by activated AMC via MAP kinase 
pathway under hypoxic condition 
      Recently, MAP kinase pathway has been identified as being responsible 
for inducing inflammatory gene expression (Bhat et al. 1998; Da et al. 1997; Won 
et al. 2001). Members of MAP kinase family include three subgroups: c-Jun 
N-terminal kinase/stress-activated protein kinase (JNK/SAPK), p38 MAP kinase 
and extracellular signal regulated kinase (ERK) (Hommes et al. 2003b). The JNK 
and p38 are cell stress and inflammation activated pathways that are associated 
with the regulation of cell apoptosis and inflammatory cytokine production 
(Kyriakis et al. 1994a; Lee et al. 1994). The ERK signalling pathway is involved 
in cell growth, proliferation and survival (Chang and Karin 2001). The JNK, p38 
 88
Discussion 
and ERK kinases are activated by phosphorylation of both tyrosine and threonine 
residues which are phosphorylated by specific upstream MAP kinase (Park et al. 
2002). Usually these phosphorylated MAP kinases result in the phosphorylation 
and subsequent activation of transcription factors, producing corresponding gene 
transcription (Hommes et al. 2003). The present results have demonstrated that the 
phosphorylated JNK and p38 levels were markedly increased at 30 min and 
gradually declined to basal levels at 4h in hypoxic microglial cells. The 
phosphorylated ERK level was increased to peak at 30min of hypoxic treatment. 
However, unlike JNK and p38, ERK1/2 level was found to be decreased only 
moderately after hypoxic exposure at 1, 2 and 4h. The c-Jun phosphorylation was 
markedly induced in a majority of microglial cell nuclei in cultures treated with 
3% oxygen for 45 min as compared with control microglial cells. Incubation of 
microglial cells with SP600125 or SB203580 which are selective inhibitors of 
JNK and p38, respectively, 30min prior to hypoxia treatment for 4h decreased the 
hypoxia-induced TNF-α and IL-1β release. On the basis of this, we suggest that 
hypoxia induce production of inflammatory cytokines such as TNF-α and IL-1β 
from activated microglial cells via MAP kinase signaling pathway.  
4.3 AMC induce PWMD through generation of TNF-α, IL-1β, MCP-1 and 
M-CSF  
TNF-α, IL-1β, MCP-1 and M-CSF produced by activated microglia in the 
hypoxic neonatal rats execute their different effects on target cells through their 
respective receptors, which leads to cell death in the hypoxic PWM. 
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4.3.1 MCP-1 mediates migration of AMC in the PWM in hypoxic neonatal 
rats  
    The present results have shown that the cell number of AMC was 
significantly increased up to 7 days in the PWM. On the other hand, there was no 
significant difference in the proliferation rate of microglia at early time points 
after hypoxic exposure when compared with the corresponding control rats. 
However, at 7 days following hypoxic exposure, the proliferation rate of AMC in 
the PWM was significantly increased. The results suggest that the rise in AMC 
soon after hypoxic exposure was attributed primarily to the migration of AMC 
from the neigboring areas of the brain or from invasion of their precursor cells, 
namely, circulating monocytes into the postnatal hypoxic brain. The increase in 
number of AMC at 7d after hypoxic exposure may partly be due to self 
proliferation as revealed by their labeling with BrdU.  
MCP-1 is a chemokine which modulates migration of activated microglial 
cells, neuroblasts and leukocytes to the inflammatory sites in CNS (Rankine et al. 
2006; Yan et al. 2007; Lu et al. 1998). Accumulating evidence suggests that 
activated microglia can produce chemokines which facilitate chemotaxis of 
leukocytes and microglial cells themselves and exacerbate the CNS inflammation 
in some diseases (Ambrosini and Aloisi 2004; Hanisch 2002). The present study 
has shown an upregulation of mRNA and protein expression of CCR2 and its 
specific localization in the AMC in the PWM. A large number of microglial cells 
were observed around the needle track in the PWM of the MCP-1 injected rats 
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when compared with sham operated or those receiving saline injection. The results 
suggest that MCP-1 either produced by activated microglial cells or administered 
intracerebrally can induce the chemotactic migration of microglial cells from other 
brain regions or blood to the PWM in the hypoxic neonatal rats. It has been 
reported that through binding with its G protein-coupled receptor CCR2, MCP-1 
induces changes in actin polymerization and subsequent reorganization of the 
actin cytoskeleton, formation of focal adhesions and pseudopod extension which 
contributes to the microglial migration when activated (Cross and Woodroofe 
1999). 
In addition, the present in vitro chemotaxis assay has confirmed that MCP-1 
released by activated microglia under hypoxic condition induced the migration of 
microglia. In the light of this, it is concluded that under hypoxic condition, 
activated microglia actively generate MCP-1 which would then induce the 
migration of microglial cells themselves either via autocrine or paracrine fashion 
since the cells exhibit MCP-1 receptor, namely, CCR2. 
It is conceivable that the migration and aggregation of microglial cells would 
aggravate the inflammatory response occurring in the PWM of hypoxic neonatal 
rats resulting in PWMD. According to the in vitro results, NF-kappaB is 
implicated in the release of MCP-1 from activated microglial cells under hypoxic 
conditions. Therefore, the present results have further extended that NF-kappaB is 




4.3.2 M-CSF promotes the release of TNF-α and IL-1β from astrocytes via 
activation of MAP kinase pathway in the PWM in hypoxic neonatal rats 
M-CSF, a multifunction cytokine, is expressed by activated microglia, 
cultured neurons and endothelia. It regulates cellular proliferation, migration, 
activation and proinflammatory response through its transmembrane receptor, 
CSF-1R (Cecchini et al. 1994; Dai et al. 2002). The present study has shown an 
up-regulated expression of CSF-1R mRNA in the PWM of neonatal rats following 
a hypoxic exposure up to 14d. Western blotting results have further demonstrated 
that protein expression of CSF-1R in the PWM was increased throughout the 
period of study i.e. up to 14d in hypoxic rats. Double immunofluorescence 
labeling has shown that CSF-1R expression was localized in the astrocytes at 7 
and 14d. Simultaneously, as mentioned earlier, astrocytes are the main source of 
inflammatory cytokines such as TNF-α and IL-1β after 7d following a hypoxic 
exposure. It is therefore, suggested that M-CSF produced by AMC in the early 
phase after hypoxia may promote the release of proinflammatory cytokines from 
astrocytes bearing CSF-1R.  
Additionally, the present in vitro results have shown that expression of 
TNF-α, IL-1β and CSF-1R in cultured astrocytes was enhanced following M-CSF 
treatment. In the light of this, it is concluded that activated microglia generate 
M-CSF that would then induce astrocytes in their production of proinflammatory 
cytokines via the CSF-1R under hypoxic conditions. 
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     The CSF-1R consists of an extracellular ligand-binding domain, a 
transmembrane domain, and an intracellular tyrosine domain (Pixley and Stanley 
2004). M-CSF binds to CSF-1R and activates the receptor by autophosphorylation 
in transmembrane domain, thereby initiating a series of membrane-proximal 
tyrosine phosphorylation cascades, resulting in rapid stimulation of gene 
transcription, protein translation and cytoskeletal remodeling (Pixley and Stanley 
2004;Yeung and Stanley 2003). The CSF-1R signaling pathways are complex and 
poorly understood at present. Recently, it has been reported that M-CSF, by 
binding to its high-affinity receptor CSF-1R, induces the proliferation of 
monocyte/macrophages via activated ERK signaling pathway (Rovida et al. 2008). 
The present results have demonstrated that the phosphorylated JNK and ERK1/2 
levels were markedly increased at 15 min and gradually declined to basal levels at 
2h in the primary cultured astrocytes treated with M-CSF protein. However, 
unlike JNK and ERK1/2, phosphorylated p38 level remained unchanged in the 
astrocytes after M-CSF treatment at 15, 30min, 1 and 2h. Incubation of astrocytes 
with SP600125, a selective inhibitor of JNK, 30 min prior to M-CSF protein 
treatment for 3h decreased the M-CSF-induced TNF-α and IL-1β expression. 
However, incubation of astrocytes with SB203580, a selective inhibitors of p38, 
30 min prior to M-CSF protein treatment for 3h did not affect the M-CSF-induced 
TNF-α and IL-1β expression. On the basis of this, we speculate that M-CSF 
induces expression of proinflammatory cytokines in astrocytes via JNK kinase 
signaling pathway. Taken together, the present results suggest that one of the 
 93
Discussion 
causative factors of a strong and persistent inflammatory response in the PWM of 
neonatal rats after hypoxic insult may be attributed to M-CSF produced by AMC. 
AMC released M-CSF would then induce the neighboring astrocytes to express 
proinflammatory cytokines such as TNF-α and IL-1β via JNK kinase signaling 
pathway. The prolonged release of TNF-α and IL-1β by AMC and astrocytes in 
temporal sequence over a protracted period may be an explanation for the 
sustained neuroinflammation in hypoxic PWM lesion. 
4.3.3 TNF-α and IL-1β result in oligodendrocytes loss, myelination deficits 
and axonal injury via binding to their respective receptors 
TNF-α acts through its TNF-R1 or TNF-R2. TNF-R1 has an intracellular death 
domain and its activation elicits caspase signal pathways that leads to cell 
apoptosis (Nakazawa et al. 2006), whereas TNF-R2 activates the Akt signaling 
pathway to promote cell growth and proliferation (Fontaine et al. 2002). In the 
CNS under physiological conditions, TNF-α is expressed to induce growth and 
proliferation of some cells via binding to TNF-R2 (Arnett et al. 2001). Under 
pathological conditions, excessive expression of TNF-α may induce apoptosis of 
some cells via binding to TNF-R1. Oligodendrocytes and astrocytes primarily 
express TNF-R1 (Dopp et al. 1997; Bohatschek et al. 2004). Our results have 
shown that the expression of TNF-R1 in the oligodendrocytes increased 
significantly after hypoxic exposure. This was coupled with increased cell death 
by apoptosis and necrosis in the PWM. The apoptotic cells were confirmed to be 
the oligodendrocytes by double immunofluorescence labeling. Concomitantly, it 
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was also found that the number of oligodendrocytes was reduced. Therefore, we 
speculate that TNF-α produced by AMC in hypoxic conditions had induced the 
oligodendrocyte apoptosis via TNF-R1 on the oligodendrocytes in hypoxic rats. 
Although IL-1β can bind equally to typeⅠ and typeⅡ IL-1R, signal transduction 
across the plasma membrane has been reported to be accomplished via the typeⅠ 
receptor (Curtis et al. 1989). At present there is no evidence that a signal can be 
transmitted through the typeⅡ receptor (Grehan et al. 1997a). Unlike TNF-α, 
IL-1β was reported as being non toxic to cells of oligodendrocyte lineage as 
oligodendrocyte apoptosis was not induced through this receptor (Vela et al. 2002). 
However, some studies have demonstrated that IL-1β can block oligodendrocyte 
proliferation at the late progenitor/pro-oligodendrocyte stage (Vela et al. 2002c). 
Our results demonstrated that the expression of IL-1R1 on the CC1 
immunoreactive positive oligodendrocytes at 7d after hypoxic exposure was 
increased significantly. It is therefore, postulated that IL-1β produced by AMC 
under hypoxic conditions may delay the white matter development and recovery 
via inhibition of oligodendrocyte progenitor proliferation. The present study has 
further found an upregulated expression of TNF-R1 and IL-1R1 on the axons in the 
PWM in hypoxic rats. This was coupled with the disruption of MBP positive 
processes of oligodendrocytes and NF-200 positive axons of neurons in the PWM. 
Ultrastructural observations have further found that many of the swollen axons 
were vesiculated and the myelin sheaths appeared distorted at 7 and 14 days after 
the hypoxic exposure. The present ultrastructural study has also shown that 
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apoptotic and necrotic cells were a common feature in the PWM of hypoxic rats 
and these cells appeared to be phagocytosed by the AMC. However, apoptotic and 
necrotic cells were rarely encountered in the PWM of the control rats. Therefore, 
based on above-mentioned results, it is postulated that overproduction of TNF-α 
and IL-1β may damage axons and delay their myelination by oligodendrocytes via 
binding to their respective receptors. 
Taken together, our studies suggest that hypoxia may initiate inflammation 
by direct activation of microglia that would damage oligodendrocytes and axons 
directly or indirectly. Therefore, we speculate that one of the mechanisms through 
which hypoxia damages the PWM may be the activation of microglial cells and 
production of inflammatory cytokines and chemokines such as TNF-α, IL-1β, 
MCP-1 and M-CSF via MAP kinase or NF-kappaB signaling pathway. AMC 
released M-CSF would then induce the neighboring astrocytes to express 
proinflammatory cytokines such as TNF-α and IL-1β via JNK kinase signaling 
pathway. The prolonged release of TNF-α and IL-1β by AMC and astrocytes in 
temporal sequence over a protracted period may cause the PWM lesion. Hence, 
microglial cells may play a pivotal role in the pathogenesis of PWMD in hypoxic 
conditions in the neonatal brain. Moreover, our finding that NF-kappaB and MAP 
kinase signaling pathways are involved in the process of the hypoxic PWMD has 

















It is evident from the overall data that activated AMC induce a strong and 
persistent inflammatory response with enormous production of inflammatory 
mediators namely, TNF-α, IL-1β, M-CSF and MCP-1 in the PWM of neonatal rats 
after a hypoxic insult. MCP-1 is a chemokine that mediates migration of microglia 
to the site of injury in CNS. Our study reveals that the cell number of AMC was 
significantly increased up to 7 days, which was due to migration of these cells. 
The AMC were readily activated as evidenced by their immediate increase in 
production of the inflammatory chemokine MCP-1 along with its receptor CCR2 
via NF-kappaB signaling pathway. It is concluded that under hypoxic condition, 
activated microglia actively generate MCP-1 which would then induce the 
migration of microglial cells in an autocrine or paracrine fashion since the cells 
exhibit MCP-1 receptor, namely, CCR2. Undoubtedly, it is suggested that the 
migration of AMC would augment the inflammatory response occurring in the 
PWM of the hypoxic neonatal rats and this may exacerbate the PWMD.  
In the present study, it has been found that the AMC in the PWM in the 
neonatal brain were the primary cellular source of M-CSF, TNF-α and IL-1β at 
early phase i.e. 24h-7d following hypoxic exposure. Concomitantly, the ambient 
astrocytes upregulated CSF-1R, TNF-α and IL-1β expression at a late stage i.e 
7-14d after hypoxic insult. Additionally, the present in vitro study has shown that 
expression of CSF-1R, TNF-α and IL-1β in cultured astrocytes was enhanced 
following M-CSF treatment via the JNK kinase signaling pathway. So the possible 
interaction between AMC and astrocytes via the above-mentioned M-CSF and its 
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receptor would lead to release of proinflammatory cytokines such as TNF-α and 
IL-1β from the latter cell type via the JNK kinase signaling pathway. It is 
suggested that the process would persist and augment the inflammatory response 
in the PWM of the hypoxic neonatal rats. Furthermore, the in vitro study has 
shown that MAP kinase signaling pathway was involved in the expression of 
TNF-α and IL-1β in microglia subjected to hypoxia. Therefore, we speculate that 
under hypoxic conditions, the AMC in the PWM in the neonatal brain produce 
inflammatory cytokines such as TNF-α and IL-1β via MAPK signaling pathway. 
Taken the above-mentioned findings together, it is suggested that in the 
progression of inflammation in the white matter of the developing brain, while the 
AMC play a major role at an early stage or acute phase in production of TNF-α 
and IL-1β, the astrocytes activated by AMC via M-CSF would be the main 
cellular source for proinflammatory cytokine production at a late stage i.e 7-14d 
after hypoxic insult.  
Expression of TNF-R1 and IL-1R1 was localized in the soma of 
oligodendrocytes and on the axons in the PWM. TNF-α and IL-1β interact with 
their respective receptors expressed on the oligodendrocytes and axons leading to 
damage of oligodendrocyte processes and myelination disturbance of the axons. 
This was also accompanied by the common occurrence of apoptosis and reduction 
in the number of oligodendrocytes. Therefore, the possible interaction between 
AMC and oligodendrocytes as well as axons via the above-mentioned 
proinflammatory cytokines and their respective receptors would lead to damage of 
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the latter. It is suggested that the decrease in the number of oligodendrocytes and 
disruption of axons would result in myelination deficits, a hallmark of PWMD.  
In conclusion, the overall data demonstrated the cellular and molecular 
events leading to PWMD in hypoxic neonatal rats, as summarized in Fig. 35. A 
better understanding of the above process will undoubtedly help provide a 
platform for developing potential therapeutic strategies for mitigation of the 
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Fig 35. An illustration demonstrates the cellular and molecular events associated 
with PWMD in the hypoxic developing brain. Hypoxia activates amoeboid 
microglial cells (AMC) or ramified microglia (RM) and, hence, induces severe 
and persistent inflammatory response with overproduction of proinflammatory 




Scope for the Future Study 
Inflammatory mediators produced by activated AMC and astrocytes are 
known to result in oligodendrocyte damage and disruption of axons. This study 
has shown that these mediators are released from AMC or astrocytes through 
MAP kinase or NF-kappaB signaling pathway under hypoxic conditions. 
Therefore, we will investigate the effect of some anti-inflammatory therapy to 
mitigate the hypoxia-induced PWMD in neonatal brain in our future studies. 
Moreover, the complex cross-talk between oligodendrocytes and axons in the 
course of myelination is disturbed in hypoxia. Thus, future research needs to 
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Fig. 2 Real time RT-PCR analysis of TNF-α, IL-1β, TNF-R1, IL-1R1 mRNA 
expression in the PWM of postnatal rats at 3, 24 h, 3, 7 and 14 d after the hypoxic 
exposure and their corresponding controls. Panel A (TNF-α), B (IL-1β), C 
(TNF-R1) and D (IL-1R1) show the graphical representation of the fold changes 
quantified by normalization to the β-actin as an internal control. Each bar 
represents the mean ± SD. There is significant difference in mRNA levels after the 



































Fig. 3 Real time RT-PCR analysis of M-CSF, CSF-1R, MCP-1 and CCR2 mRNA 
expression in the PWM of postnatal rats at 3, 24 h, 3, 7 and 14 d after the hypoxic 
exposure and their corresponding controls. Panel A (M-CSF), B (CSF-1R), C 
(MCP-1) and D (CCR2) show the graphical representation of the fold changes 
quantified by normalization to the β-actin as an internal control. Each bar 
represents the mean ± SD. There is significant difference in mRNA levels after the 







































Fig. 4 Western blotting of TNF-α, IL-1β, TNF-R1 and IL-1R1 protein expression 
in the PWM tissue supernatants of rats at 3 , 24 h, 3 , 7  and 14 d after the 
hypoxic exposure and their corresponding controls (Cn). The upper panels (A) 
show TNF-α (30 kDa) , IL-1β (17 kDa) , TNF-R1 (55 kDa), IL-1R1 (80 kDa) and 
β-actin (42kDa) immunoreactive bands, respectively. The lower panels (B, 
TNF-α), (C IL-1β), (D, TNF-R1) and (E, IL-1R1) are bar graphs showing 
significant changes in the optical density following hypoxic exposure when 
compared with their corresponding controls (mean ± SD). β-actin  as internal 










Fig. 5 M-CSF, CSF-1R, CCR  and MCP-1 protein expression in the PWM at 3, 
24h, 3, 7 and 14 days after hypoxic exposure and corresponding control rats. A 
shows M-CSF (18.5KDa), CSF-1R (170KDa) and β-actin (42KDa) 
immunoreactive bands, respectively. B, C shows bar graphs depicting significant 
changes in the optical density of M-CSF and CSF-1R, respectively, following 
hypoxic exposure when compared with their corresponding controls. Bar graph D 
shows CCR  (47KDa) and β-actin (42KDa) immunoreactive bands, respectively. 
Bar graph in E shows significant changes in the optical density of CCR  following 
hypoxic exposure when compared with their corresponding controls. F shows that 
hypoxia triggered release of MCP-1 is significantly increased at 3, 24h, 3, 7 and 
14d. Significant difference in mRNA and protein levels in the PWM after the 









































Fig. 6 Confocal images showing the distribution of lectin labelled (A, D, G, J; 
green), TNF-α (B, E; red) and IL-1β (H, K; red) immunoreactive amoeboid 
microglial cells (AMC; arrows) in the PWM at 24h after the hypoxic exposure and 
the corresponding control rat. The colocalized expression of lectin and TNF-α as 
well as lectin and IL-1β in AMC can be seen in C and F, I and L. The expression 
of TNF-α (E) and IL-1β (K) in AMC (arrows) is markedly enhanced after the 
















Fig. 7 Confocal images showing the distribution of GFAP labeled (A, D, G, J, M, 
P; green), and TNF-α (B, E, H, K, N, Q; red) immunoreactive astrocytes (arrows) 
in the PWM at 24h, 7 and 14d after the hypoxic exposure and the corresponding 
control rats. The colocalized expression of GFAP and TNF-α in astrocytes can be 
seen in C, F, I, L, O and R. Note TNF-α expression in astrocytes (arrows) is 











































Fig. 8 Confocal images showing the distribution of GFAP labeled (A, D, G, J; M, 
P, green), and IL-1β (B, E, H, K, N, Q; red) immunoreactive astrocytes (arrows) 
in the PWM at 24h, 7 and 14d after the hypoxic exposure and the corresponding 
control rats. The colocalized expression of GFAP and IL-1β in astrocytes can be 
seen in C, F, I, L, O and R. Note IL-1β expression in astrocytes (arrows) is 











































Fig. 9 Confocal images showing the distribution of CC  (A, D, G, J; green) , 
TNF-R  (B, E; red)  and IL-1R  (H, K; red) in oligodendrocytes (arrows) and 
their processes in the PWM at 7d after the hypoxic exposure and the 
corresponding control. The colocalized expression of CC  with TNF-R  and 
IL-1R  is depicted in C and F, I and L. Note the expression of TNF-R and IL-1R  
is upregulated after the hypoxic exposure. The percentage of TNF-R and IL-1R
immunoreactive positive oligodendrocytes is significantly increased as shown in 






































Fig. 10 Confocal images showing the distribution of NF-200 (A, D, G, J; green) , 
TNF-R  (B, E; red)  and IL-1R  (H, K; red) in axons (arrows) in the PWM at 14d 
after the hypoxic exposure and the corresponding control. Colocalized expression 
of NF-200 with TNF-R  and IL-1R  is depicted in C and F, I and L. Note the 












































Fig. 11 Confocal images showing the distribution of lectin labeled (A, D, G, J; 
green), and M-CSF (B, E, H, K; red) immunoreactive amoeboid microglial cells 
(AMC; arrows) in the PWM at 3 and 7d after the hypoxic exposure and in the 
corresponding control rat. The colocalized expression of lectin and M-CSF in 
AMC can be seen in C, F, I and L. Note M-CSF expression in AMC (arrows) is 












































Fig. 12 Confocal images showing the distribution of GFAP labeled (A, D, G, J; 
green), and CSF-1R (B, E, H, K; red) immunoreactive astrocytes (arrows) in the 
PWM at 7 and 14d after the hypoxic exposure and the corresponding control rats. 
The colocalized expression of GFAP and CSF-1R in astrocytes can be seen in C, 
F, I and L. Note CSF-1R expression in astrocytes (arrows) is markedly enhanced 











































Fig. 13 Confocal images showing the distribution of lectin labeled (A, D, G, J; 
green), and MCP-1 (B, E, H, K; red) immunoreactive AMC (arrows) in the PWM 
at 3 and 24h after the hypoxic exposure and the corresponding control rats. Lectin 
labeling clearly overlaps MCP-1 immunofluorescence in C, F, I and L. Note 
MCP-1 expression in AMC (arrows) is markedly enhanced after the hypoxic 











































Fig. 14 Confocal images showing the distribution of lectin labeled (A, D, G, J; 
green), and MCP-1 (B, E, H, K; red) immunoreactive AMC (arrows) in the PWM 
at 3 and 7d after the hypoxic exposure and the corresponding control rats. 
Colocalized expression of lectin and MCP-1 in AMC is evident in C, F, I and L. 
The expression of MCP-1 in AMC (arrows) is markedly enhanced after the 











































Fig. 15 Confocal images showing the distribution of lectin labeled (A, D, G, J; 
green), and CCR  (B, E, H, K; red) immunoreactive AMC (arrows) in the PWM at 
3h and 3d after the hypoxic exposure and the corresponding control rats. 
Colocalized expression of lectin and CCR  in AMC is evident in C, F, I and L. 
The expression of CCR  in AMC (arrows) is markedly enhanced after the hypoxic 











































Fig. 16 MBP and NF-200 protein expression in the PWM at 14 days after the 
hypoxic exposure and the corresponding control rats. A shows MBP and β-actin 
(42KDa) immunoreactive bands, respectively. Bar graph in B shows significant 
decrease in the optical density of MBP following hypoxic exposure when 
compared with the corresponding controls (* p< 0.01). Confocal images show the 
expression of MBP (C, green), NF-200 (D, red), and co-localized expression of 
MBP and NF-200 (E) in the PWM at 14 days of control rats. F-H show the 
expression of MBP (F, green), NF-200 (G, red), and co-localized expression of 
MBP and NF-200 (H) at 14 days after the hypoxic exposure. Note the MBP 
positive processes and NF-200 positive axons are disrupted following the hypoxic 







































Fig. 17 Confocal images showing CC  immunolabeled oligodendrocytes 
(arrows)(A, D; red) and apoptotic cells (arrows)(B, E; green) as detected by 
TUNEL in the PWM of a control and a hypoxic rat at 7d after the hypoxic 
exposure. The colocalized expression of CC  and TUNEL labeling can be seen in 
C and F. Bar graphs in G and H show the significant increase in percentage of 
apoptotic nuclei (G) and decrease in the number of CC1 positive 
oligodendrocytes/mm  (H) in the PWM after the hypoxic exposure (* p < 0.01). 














































Fig. 18 Electron micrographs showing necrotic cells in the PWM at 24h (A) and 
7d (C) after the hypoxic exposure. B and D show apoptotic cells. E and F show 
AMC with internalized necrotic (E) and apoptotic (F) cells (arrows) in the PWM 













































Fig. 19 Electron micrographs of non-myelinated (A, B, C) and myelinated (B, D) 
axons (AX) in the PWM at 7 and 14 days after the hypoxic exposure. Note the 
swelling and vacuolation of non-myelinated axons (A, C) and distortion of myelin 










































Fig. 20 Confocal images showing the distribution of lectin labeled (A, D, G, J; 
green), and BrdU (B, E, H, K; red) immunoreactive amoeboid microglial cells 
(AMC) in the PWM at 3 and 24h after the hypoxic exposure and the 
corresponding control rats. Colocalized expression of lectin and BrdU is seen in 
merged images in C, F, I and L. Note the number of AMC is markedly increased 
in hypoxic rats; however, fewer BrdU positive AMC are observed. Bar graph in M 
shows a significant increase in the cell number of AMC in the PWM at 3 and 24h 
after the hypoxic exposure when compared with their corresponding controls ( * 
p < 0.01). Bar graph in N shows the percentage of BrdU positive AMC against the 
total AMC population at 3 and 24h after the hypoxic exposure when compared 






























Fig. 21 Confocal images showing the distribution of lectin labeled (A, D, G, J; 
green), and BrdU (B, E, H, K; red) immunoreactive AMC in the PWM at 3 and 7d 
after the hypoxic exposure and the corresponding control rats. Merged images in 
C, F, I and L show the colocalized expression of lectin and BrdU in these cells. 
The number of AMC is drastically increased. BrdU positive AMC is noticeably 
increased at 7d after the hypoxic exposure when compared with the corresponding 
control. Bar graph in M shows a significant increase in the cell number of AMC in 
the PWM at 3 and 7d after the hypoxic exposure when compared with their 
corresponding controls (* p < 0.01). Bar graph in N shows the percentage of BrdU 
positive AMC against the total AMC population at 3 and 7d after the hypoxic 
exposure when compared with their corresponding controls (* p < 0.01). Scale 
































Fig. 22 MCP-1 induces microglial cell migration in vivo. Few lectin positive 
microglial cells are distributed in the PWM (arrowhead) of the sham-operated (A) 
and saline injected rats (D). Many lectin positive microglial cells migrate to 
MCP-1 (500 ng/mL) injection site (G). Images in B–C, E-F, H-I are enlarged view 
of areas outlined in A, D and G. Arrowheads indicate lectin positive microglial 
cells in the ipsilateral or contralateral PWM. Arrows represent needle track in the 
PWM. Boxed area represents the injection site and its peripheral areas; circled 
area represents the corresponding area in the contralateral side. Bar graph in J 
shows a significant increase in the cell number of AMC in the PWM ipsilateral to 
MCP-1 injection when compared to the corresponding areas on the contralateral 
side and those given saline injection or sham-operated rats ( * p < 0.01). Scale bar: 





































Fig. 23 MCP-1 induces microglial cell migration in vivo. Few OX-42 positive 
microglial cells are distributed in the PWM (arrowhead) of the sham-operated (A) 
and saline injected rats (D). Many OX-42 positive microglial cells migrate to 
MCP-1 (500 ng/mL) injection site (G). Images in B–C, E-F, H-I are enlarged view 
of areas outlined in A, D and G. Arrowheads indicate OX-42 positive microglial 
cells in the ipsilateral or contralateral PWM. Arrows represent needle track in the 
PWM. Boxed area represents the injection site and its peripheral areas; circled 
area represents the corresponding area in the contralateral side. Bar graph in J 
shows a significant increase in the cell number of AMC in the PWM ipsilateral to 
MCP-1 injection when compared to the corresponding areas on the contralateral 
side and those given saline injection or sham-operated rats ( * p < 0.01). Scale bar: 








































Fig. 24 mRNA expression of TNF-α, IL-1β, M-CSF and MCP-1 in cultured 
control microglia and at 1, 2, 4 and 6 h after hypoxic exposure. A (TNF-α mRNA), 
B (IL-1β mRNA), C (M-CSF mRNA) and D (IL-1β mRNA) show the graphical 
representation of the fold changes quantified by normalization to the β-actin as an 
internal control. Significant differences in mRNA and protein levels in microglial 











































Fig. 25 Protein expression of TNF-α, IL-1β, M-CSF and MCP-1 in cultured 
control microglia and at 1, 2, 4 and 6 h after hypoxic exposure. The panels A 
show TNF-α (30 kDa), IL-1β (17 kDa) and M-CSF (18.5 kDa) immunoreactive 
protein bands. B, C and D are bar graphs showing changes in the optical density 
of TNF-α, IL-1β and M-CSF, respectively, following hypoxic exposure. Bar graph 
E is ELISA analysis showing hypoxia triggered release of MCP-1 is significantly 
increased in the medium at 1, 2, 4 and 6h after hypoxic exposure. Significant 
differences in protein levels in microglial cells after the hypoxic exposure are 





































Fig. 26 Confocal images of cultured control microglia showing the expression of 
lectin (A, G; green), TNF-α (B, red),   IL-1β (H, red) and co-localized 
expression of lectin and TNF-α (C) as well as lectin and  IL-1β (I). D-F show the 
expression of lectin (D, green), TNF-α (E, red) and co-localized expression of 
lectin and TNF-α (F) after treatment with 3% oxygen for 4h. Note the elevated 
expression of TNF-α following treatment with 3% oxygen for 4h (E) as compared 
with the control cells (B). J-L show the expression of lectin (J, green), IL-1β (K, 
red) and co-localized expression of lectin and IL-1β (L) after treatment with 3% 
oxygen for 4h. The expression of IL-1β is greatly increased in the microglial cells 
after hypoxic exposure for 4h. The bar graph M shows a significant increase in the 
percentage of TNF-α and IL-1β immunoreactive microglia after the hypoxic 






































Fig. 27 Confocal images of cultured control microglia showing the expression of 
lectin (A, G; green), M-CSF (B, red),   MCP-1 (H, red) and co-localized 
expression of lectin and M-CSF (C) as well as lectin and MCP-1 (I). D-F show the 
expression of lectin (D, green), M-CSF (E, red) and co-localized expression of 
lectin and M-CSF (F) after treatment with 3% oxygen for 4h. Note the elevated 
expression of M-CSF following treatment with 3% oxygen for 4h (E) as compared 
with the control cells (B). J-L show the expression of lectin (J, green), MCP-1 (K, 
red) and co-localized expression of lectin and MCP-1 (L) after treatment with 3% 
oxygen for 4h. The expression of MCP-1 is greatly increased in the microglial 








































Fig. 28 Western blot analysis showing hypoxia induced TNF-α and IL-1β 
production via activation of MAPK pathway in microglia. The panels A, B, C 
show JNK, p38, ERK phosphorylation and total JNK, p38, ERK immunoreactive 
bands. The panels D, E and F, G show immunoreactive bands which indicate that 
SP600125 (a JNK inhibitor) and SB203580 (a p38 inhibitor) suppress the 
expression TNF-α and IL-1β, respectively, in the microglial cells after hypoxic 
exposure for 4h. H-J are bar graphs showing significant changes in the optical 
density of JNK, p38 and ERK phosphorylation, respectively, following hypoxic 
exposure. K-N are bar graphs showing significant suppression in expression of 







































Fig. 29 Confocal images of cultured microglia showing the expression of the 
N-terminal phosphorylated c-JUN (phos-c-JUN) (B, red), counter-staining with 
DAPI (A, blue), and co-localized expression of DAPI and phos-c-JUN (C). D-F 
show the expression of phos-c-JUN (E, red), counter-staining with DAPI (D, blue), 
and co-localized expression of DAPI and phos-c-JUN (F) after treatment of cells 
with 3% oxygen for 45 min. The expression of phos-c-JUN in the nucleus is 
greatly increased after hypoxia for 45 min. G represents the percentage of 
phospho-c-JUN positive control microglial cells and cells treated with 3% oxygen 









































Fig. 30 Western blot analysis showing hypoxia induced MCP-1 production via 
activation of NF-kappaB signaling pathway in microglia. Panels A, B, C, D show 
phos-NF-kappaB, NF-kappaB, phos-IkappaB and IkappaB immunoreactive bands. 
E-G are bar graphs showing significant changes in the optical density of 
phos-NF-kappaB, NF-kappaB and phos-IkappaB, respectively, following hypoxic 
exposure. H is a bar graph showing no significant change in the optical density of 
IkappaB following hypoxic exposure. In bar graph I, ELISA analysis shows that 
BAY 11-7082 (a NF-kappaB inhibitor) suppresses the release of MCP-1 in the 







































Fig. 31 mRNA and protein expression of TNF-α, IL-1β and CSF-1R in cultured 
control astrocytes and at 3 , 6 , 12 and 24 h after treatment with M-CSF in A-G. A 
(TNF-α mRNA), B (IL-1β mRNA) and C (CSF-1R mRNA) show the graphical 
representation of the fold changes quantified by normalization to the β-actin as an 
internal control.  Panel D shows TNF-α (30 kDa), IL-1β (17 kDa) and CSF-1R 
(170kDa) immunoreactive protein bands. E, F and G are bar graphs showing 
changes in the optical density of TNF-α, IL-1β and CSF-1R, respectively, 
following M-CSF treatment. Significant differences in mRNA and protein levels 
in astrocytes with M-CSF treatment are evident when compared with controls, * 





































Fig. 32 Confocal images of cultured control astrocytes showing the expression of 
GFAP (A, G, M; green), TNF-α (B, red), IL-1β (H, red), CSF-1R (N, red) and 
co-localized expression of GFAP and TNF-α (C), GFAP and IL-1β (I) as well as 
GFAP and CSF-1R (O). D-F show the expression of GFAP (D, green), TNF-α (E, 
red) and co-localized expression of GFAP and TNF-α (F) after treatment with 
M-CSF for 12h. J-L show the expression of GFAP (J, green), IL-1β (K, red) and 
co-localized expression of GFAP and IL-1β (L) after treatment with M-CSF for 
12h. P-R show the expression of GFAP (P, green), CSF-1R (Q, red) and 
co-localized expression of GFAP and CSF-1R (R) after treatment with M-CSF for 
12h. The expression of TNF-α (E), IL-1β (K) and CSF-1R (Q) is greatly increased 
in the astrocytes after treatment with M-CSF for 12h as compared with the control 




































Fig. 33 Western blot analysis showing M-CSF induced TNF-α and IL-1β 
production via activation of MAPK pathway in astrocytes. Panels A, B and C 
show JNK, p38, ERK phosphorylation and total JNK, p38, ERK immunoreactive 
bands. Panels D and E show immunoreactive bands which indicate that SP600125 
(a JNK inhibitor) suppress the expression TNF-α and IL-1β, respectively, in the 
astrocytes after M-CSF treatment for 3h. Panels F and G show immunoreactive 
bands which indicate that SB203580 (a p38 inhibitor) can not suppress the 
expression TNF-α and IL-1β, respectively, in the astrocytes after M-CSF treatment 
for 3h. H and J are bar graphs showing significant changes in the optical density 
of JNK and ERK phosphorylation, respectively, following treatment with M-CSF. 
I is a bar graph showing no significant changes in the optical density of p38 
phosphorylation following treatment with M-CSF. K-L are bar graphs showing 
significant suppression in expression of TNF-α and IL-1β by SP600125, 
respectively. M-N are bar graphs showing no significant suppression in expression 








Fig. 34 In vitro chemotaxis assay shows the effects of DMEM, control, hypoxia 
4h and hypoxia 4h + anti-MCP-1 antiserum, hypoxia 4h + unrelated antiserum 
treated microglial cultures on the migration of microglia. (A) Chamotaxis assay 
results show a few crystal violet-stained microglia transmigrate through the 
membrane of insert in a transwell chamber in the DMEM medium. Optimized 
conditioned medium derived from hypoxia treated microglial cultures attracts 
more microglial cells than the control medium. The number of hypoxia-induced 
transmigrated microglia is markedly reduced in hypoxia 4h + anti-MCP-1 
antiserum treated medium. The medium of hypoxia treated culture with rabbit 
anti-MCP-1 antiserum attracts less microglia than that from hypoxia 4h 
+ unrelated antiserum (rabbit anti-iNOS). (B) Quantitative analysis shows that 
hypoxia-induced migration is suppressed significantly by anti-MCP-1 antiserum. 
Data represent the mean percentage of migrated cells per microscopic field 
relative to spontaneous migration toward the DMEM medium (0.5% BSA). 
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A. Control Lectin B. Control TNF-α C. Control Merge
D. Hypoxia 24h Lectin E. Hypoxia 24h TNF-α F. Hypoxia 24h Merge
G. Control Lectin H. Control IL-1β I. Control Merge
J. Hypoxia 24h Lectin K. Hypoxia 24h IL-1β L. Hypoxia 24h Merge
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G Control 7d GFAP H Control 7d TNF-α I Control 7d Merge
J Hypoxia 7d GFAP K Hypoxia 7d TNF-α L Hypoxia 7d Merge
M Control 14d GFAP N Control 14d TNF-α O Control 14d Merge
P Hypoxia 14d GFAP Q Hypoxia 14d TNF-α R Hypoxia 14d Merge
Fig.7
A Control 24h GFAP B Control 24h TNF-α C Control 24h Merge
D Hypoxia 24h GFAP E Hypoxia 24h TNF-α F Hypoxia 24h Merge
144
G Control 7d GFAP
J Hypoxia 7d GFAP
H Control 7d IL-1β
K Hypoxia 7d IL-1β
I Control 7d Merge
L Hypoxia 7d Merge
M Control 14d GFAP
P Hypoxia 14d GFAP
N Control 14d IL-1β
Q Hypoxia 14d IL-1β
O Control 14d Merge
R Hypoxia 14d Merge
Fig.8
A Control 24h GFAP
D Hypoxia 24h GFAP
B Control 24h IL-1β
E Hypoxia 24h IL-1β
C Control 24h Merge
F Hypoxia 24h Merge
146
Fig.9
F. Hypoxia 7d Merge
A. Control CC1 B. Control TNF-R1 C. Control Merge
D. Hypoxia 7d CC1 E. Hypoxia 7d TNF-R1
G. Control CC1 H. Control IL-1R1 I. Control Merge
J. Hypoxia 7d CC1 K. Hypoxia 7d IL-1R1 L. Hypoxia 7d Merge
148
A control 14d NF-200
F hypoxia 14d MergeE hypoxia 14d TNF-R1D hypoxia 14d NF-200
C control 14d MergeB control 14d TNF-R1
G control 14d NF-200
L hypoxia 14d MergeK hypoxia 14d IL-1R1J hypoxia 14d NF-200
I control 14d MergeH control 14d IL-1R1
Fig.10
150
A Control 3d Lectin B Control 3d M-CSF
E Hypoxia 3d M-CSF
C Control 3d Merge
D Hypoxia 3d Lectin F Hypoxia 3d Merge
G Control 7d Lectin H Control 7d M-CSF
J Hypoxia 7d Lectin H Hypoxia 7d M-CSF
I Control 7d Merge
L Hypoxia 7d Merge
Fig.11
152
A Control 7d GFAP B Control 7d CSF-1R C Control 7d Merge
D Hypoxia 7d GFAP E Hypoxia 7d CSF-1R F Hypoxia 7d Merge
G Control 14d GFAP H Control 14d CSF-1R I Control 14d Merge
K Hypoxia 14d CSF-1R L Hypoxia 14d MergeJ Hypoxia 14d GFAP
Fig.12
154
A Control Lectin B Control MCP-1 C Control Merge
D Hypoxia 3h Lectin E Hypoxia 3h MCP-1 F Hypoxia 3h Merge
G Control Lectin H Control MCP-1 I Control Merge







J Hypoxia 7d Lectin K Hypoxia 7d MCP-1
C Control Merge
E Hypoxia 3d MCP-1D Hypoxia 3d Lectin F Hypoxia 3d Merge
I Control Merge




A Control Lectin B Control CCR2
D Hypoxia 3h Lectin E Hypoxia 3h CCR2
G Control Lectin H Control CCR2
J Hypoxia 3d Lectin K Hypoxia 3d CCR2
C Control Merge
F Hypoxia 3h Merge
I Control Merge
L Hypoxia 3d Merge
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F hypoxia 14d MBP
C control 14d MBP
H hypoxia 14d MergeG hypoxia 14d NF-200
E control 14d MergeD control 14d NF-200





























































A. Control CC1 B. Control apoptosis C. Control Merge


























































A Control Lectin B Control BrdU C Control Merge
D Hypoxia 3h Lectin E Hypoxia 3h BrdU F Hypoxia 3h Merge
G Control Lectin H Control BrdU I Control Merge






































































E Hypoxia 3d BrdU
H Control BrdU
D Hypoxia 3d Lectin
G Control Lectin
J Hypoxia 7d Lectin K Hypoxia 7d BrdU
F Hypoxia 3d Merge
I Control Merge
L Hypoxia 7d Merge
Fig.21
M.







































































D. 0.9% NaCl injection 8h










































A. Control B. Ipsilateral OX42 C. Contralateral OX42
D. 0.9% NaCl injection 8h E. Ipsilateral OX42 F. Contralateral OX42


















































































































































































































































A. Control Lectin B. Control TNF-ɑ C. Control Merge
D. Hypoxia 4h Lectin E. Hypoxia 4h TNF-ɑ F. Hypoxia 4h Merge
G. Control Lectin H. Control IL-1β I. Control Merge
J. Hypoxia 4h Lectin K. Hypoxia 4h IL-1β L. Hypoxia 4h Merge
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A Control Lectin B Control M-CSF C Control Merge
D Hypoxia 4h Lectin E Hypoxia 4h M-CSF F Hypoxia 4h Merge
A2 hypo 4h
G Control Lectin H Control MCP-1 I Control Merge
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control   hypoxia 4h  hypoxia 4h+JNK inhibitor























































control   hypoxia 4h  hypoxia 4h+p38 inhibitor


































































































A.. Control DAPI B.  Control phos-c-JUN C.  Control Merge








































































































































































































































































































A Control GFAP B Control TNF-α C Control Merge
D M-CSF 12h GFAP E M-CSF 12h TNF-α F M-CSF 12h Merge
G Control GFAP H Control IL-1β I control Merge
J M-CSF 12h GFAP K M-CSF 12h IL-1β L M-CSF 12h Merge
Fig.32
M Control GFAP N Control CSF-1R O Control Merge





























control    M-CSF 3h   M-CSF 3h+JNK inhibitor




control   M-CSF 3h  M-CSF 3h+p38 inhibitor















































































































































DMEM Control Medium Hypo 4h 











DMEM control hypoxia 4h Hypoxia 4h +
antiMCP-1
Hypoxia 4h +
antiserum
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